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ABSTRACT 
Drug resistance is the most important factor that influences the successful treatment of 
individuals infected with the human immunodeficiency virus type 1 (HIV-1), the 
causative organism of the acquired immunodeficiency syndrome (AIDS).  Tremendous 
advances in our understanding of HIV and AIDS have led to the development of Highly 
Active Antiretroviral Therapy (HAART), a combination of drugs that includes HIV-1 
reverse transcriptase, protease, and more recently, integrase and entry inhibitors, to 
combat the virus.  Though HAART has been successful in reducing AIDS-related 
morbidity and mortality, HIV rapidly evolves resistance leading to therapy failure.  Thus, 
a better understanding of the mechanisms of resistance will lead to improved drugs and 
treatment regimens. 
Protease inhibitors (PIs) play an important role in anti-retroviral therapy.  The 
development of resistance mutations within the active site of the protease greatly reduces 
its affinity for the protease inhibitors.  Frequently, these mutations reduce catalytic 
efficiency of the protease leading to an overall reduction in viral fitness.  In order to 
overcome this loss in fitness the virus evolves compensatory mutations within the 
protease cleavage sites that allow the protease to continue to recognize and cleave its 
substrates while lowering affinity for the PIs.  Improved knowledge of this substrate co-
evolution would help better understand how HIV-1 evolves resistance and thus, lead to 
improved therapeutic strategies.  Sequence analyses and structural studies were 
performed to investigate co-evolution of HIV-1 protease and its cleavage sites.  Though a 
  vii 
few studies reported the co-evolution within Gag, including the protease cleavage sites, a 
more extensive study was lacking, especially as drug resistance was becoming 
increasingly severe.  
In Chapter II, a small set of viral sequences from infected individuals were analyzed for 
mutations within the Gag cleavage sites that co-occurred with primary drug resistance 
mutations within the protease.  These studies revealed that mutations within the p1p6 
cleavage site coevolved with the nelfinavir-resistant protease mutations.  As a result of 
increasing number of infected individuals being treated with PIs leading to the 
accumulation of PI resistant protease mutations, and with increasing efforts at genotypic 
and phenotypic resistance testing, access to a larger database of resistance information 
has been made possible.  Thus in Chapter III, over 39,000 sequences were analyzed for 
mutations within NC-p1, p1-6, Autoproteolysis, and PR-RT cleavage sites and several 
instances of substrate co-evolution were identified.  Mutations in both the NC-p1 and the 
p1-p6 cleavage sites were associated with at least one, if not more, primary resistance 
mutations in the protease.   
Previous studies have demonstrated that mutations within the Gag cleavage sites enhance 
viral fitness and/or resistance when they occur in combination with primary drug 
resistance mutations within the protease.  In Chapter III viral fitness in the presence and 
absence of cleavage site mutations in combination with primary drug resistant protease 
mutations was analyzed to investigate the impact of the observed co-evolution.  These 
studies showed no significant changes in viral fitness.  Additionally in Chapter III, the 
 viii 
impact of these correlating mutations on phenotypic susceptibilities to various PIs was 
also analyzed.  Phenotypic susceptibilities to various PIs were altered significantly when 
cleavage site mutations occurred in combination with primary protease mutations. 
In order to probe the underlying mechanisms for substrate co-evolution, in Chapter IV, 
X-ray crystallographic studies were performed to investigate structural changes in 
complexes of WT and D30N/N88D protease variants and the p1p6 peptide variants.  
Peptide variants corresponding to p1p6 cleavage site were designed, and included 
mutations observed in combination with the D30N/N88D protease mutation.  Structural 
analyses of these complexes revealed several correlating changes in van der Waals 
contacts and hydrogen bonding as a result of the mutations.  These changes in 
interactions suggest a mechanism for improving viral fitness as a result of co-evolution. 
This thesis research successfully identified several instance of co-evolution between 
primary drug resistant mutations in the protease and mutations within NC-p1 and p1p6 
cleavage sites.  Additionally, phenotypic susceptibilities to various PIs were significantly 
altered as a result of these correlated mutations.  The structural studies also provided 
insights into the mechanism underlying substrate co-evolution.  These data advance our 
understanding of substrate co-evolution and drug resistance, and will facilitate future 
studies to improve therapeutic strategies. 
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CHAPTER I 
INTRODUCTION 
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Drug resistance has become a persistent problem in treating highly communicable 
diseases such as tuberculosis and acquired immunodeficiency syndrome (AIDS) (Dorman 
and Chaisson, 2007; Fischbach and Walsh, 2009; Shafer and Schapiro, 2005).  Since the 
discovery of the human immunodeficiency virus type 1 (HIV-1) as the causative agent of 
AIDS (Chermann et al., 1983), research has led to the development of antiretroviral 
therapies that have significantly reduced HIV-1-related morbidity and mortality 
(Chermann et al., 1983; Palella et al., 1998).  HIV-1, however, evolves rapidly due to 
lack of proof-reading mechanism by the reverse transcriptase, rapid replication rate and 
the selective pressures of antiretroviral therapy, leading to emergence and transmission of 
drug-resistant viruses resulting in therapy failure (Shafer and Schapiro, 2005). 
Current antiretroviral strategies for treating HIV-1 infections include drugs that inhibit 
the viral enzymes reverse transcriptase, protease, and more recently, integrase.  Due to 
the pivotal role of HIV-1 protease in viral maturation, protease inhibitors are one of the 
most important components of antiretroviral therapy (Kohl et al., 1988; Kramer et al., 
1986).  However, the emergence of resistance to protease inhibitors has significantly 
reduced their efficacy (Shafer and Schapiro, 2005).  HIV-1 evolves resistance to protease 
inhibitors by the selection of mutations not only in the protease (Mammano et al., 2000; 
Martinez-Picado et al., 1999) but elsewhere in the genome, including the protease 
substrate sites within Gag and GagPol (Doyon et al., 1996; Zhang et al., 1997).   
At the commencement of this study, protease cleavage site mutations had been observed 
in a few studies as a compensatory mechanism for the deleterious effects of mutations 
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within the protease (Mammano et al., 2000; Martinez-Picado et al., 1999).  Although 
associations between specific mutations in the protease and its cleavage sites had been 
reported, they were still fairly uncommon.  Therefore, one main goal of my thesis 
research was to investigate correlations between protease mutations that are the primary 
cause of resistance to protease inhibitors, and mutations within the substrate-cleavage 
sites.  Another goal was to analyze the impact of these associated mutations on 
replicative capacity susceptibility to protease inhibitors.   
Although biochemical and virological aspects of co-evolving protease-substrate 
mutations had been studied previously (Maguire et al., 2002; Zennou et al., 1998), the 
structural basis for this coevolution was not well understood.  Therefore, another goal of 
my research was to investigate conformational changes within both the protease and 
substrate as a result of the associated mutations using the example of the p1-p6 cleavage 
site, which is known to co-evolve with the D30N/N88D protease mutations that are a 
signature of NFV resistance (Kolli, Lastere, and Schiffer, 2006). 
In this chapter, I will introduce the epidemiology, treatment and socio-economic impact 
of HIV-1/AIDS.  I will then briefly describe the HIV-1 life cycle and go on to focus on 
the HIV-1 protease.  I will present in detail the structure and function of the protease, 
mechanism of substrate recognition, and the development of resistance to protease 
inhibitors.  Finally, I will discuss current knowledge on the co-evolution of mutations in 
HIV-1 protease and its substrates as well as the contribution of this co-evolution to viral 
fitness and resistance to protease inhibitors. 
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AIDS 
Acquired immunodeficiency syndrome is caused by infection with HIV-1, which 
primarily infects and kills CD4 T cells, macrophages and dendritic cells.  The declining 
number of CD4 T cells and consequent loss in cell-mediated immunity leaves infected 
individuals highly susceptible to opportunistic infections, resulting in full-blown AIDS, 
and eventually death.  Infections that commonly affect HIV-infected individuals include 
tuberculosis, pneumonia and toxoplasmosis.  Infected individuals are also prone to 
several malignancies as a result of co-infections with oncogenic viruses like Epstein-Barr 
virus, Kaposi’s sarcoma-associated herpes virus and human papilloma virus.  HIV-1 is 
transmitted through direct contact of a mucous membrane or blood with a body fluid 
containing the virus. 
Currently, most HIV-1 infected individuals in resource-rich countries receive highly 
active antiretroviral therapy (HAART) that has successfully slowed the progression to 
AIDS and improved patients’ quality of life.  HAART consists of a combination of at 
least 3 drugs from at least 2 classes: reverse transcriptase and protease inhibitors.  These 
drugs have been successful to an extent, but drug-resistant strains of HIV-1 have emerged 
due to a combination of factors: the biology of HIV, poor adherence, and anatomical or 
cellular reservoirs that are inaccessible to the drugs.  Resistance has considerably 
diminished susceptibility of HIV-1 to various drugs and as a result, driving research 
efforts in discovering new viral and cellular targets.  Of equal importance in improving 
treatment of AIDS are studies on the mechanism of action of various drugs, HIV-1 
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biology and other factors that contribute to and help improve understanding of drug 
resistance. 
AIDS was first reported in the US in 1981 by the Centers for Disease Control.  Since then 
more than 25 million individuals have died from AIDS. In 2007, the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO), 
estimated that 33 million people are now infected worldwide.  That year alone, AIDS-
related complications caused 2 million deaths and about 2.7 million people were newly 
infected with HIV-1.  Despite better public education, improved understanding of HIV-1 
and AIDS, and access to newer treatments, the disease has reached pandemic proportions 
in sub-Saharan Africa, India, and other regions of South and South-East Asia.  The 
emergence of highly resistant HIV-1 strains has made it harder to keep AIDS in check.   
HIV/AIDS has wide-ranging impacts on every aspect of society, especially in the 
resource-poor countries of Africa and Asia.  Families of affected individuals are 
burdened by the staggering medical costs, loss of income, and social stigma.  Agriculture 
and business are often severely affected due to the loss of productive workers.  
Healthcare systems do not have the capacity to take on the additional demands of infected 
individuals battling AIDS-related complications.  All these factors directly reduce 
national economic growth and development. 
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HIV-1 LIFE CYCLE 
Human immunodeficiency virus, the causative organism of AIDS, is a member of the 
family retroviridae and genus lentivirus (Chiu et al., 1985).  Lentiviruses or “slow 
viruses” are so named for the long interval between initial infection and onset of 
symptomatic disease.  HIV-1 has 2 copies of a positive-sense 9.2kb RNA genome that 
encodes the viral proteins, both structural and functional.  The gag gene encodes 
structural proteins that make up the viral skeleton, the pol gene encodes the three 
enzymes (protease, reverse transcriptase, and integrase), the env gene encodes the 
envelope proteins.  The HIV-1 genome also has six other genes encoding the regulatory 
proteins – Tat, Rev, Vif, Vpr, Vpu and Nef, whose functions are yet to be completely 
understood.  Briefly, the viral life cycle consists of the following steps: binding and entry, 
uncoating and reverse transcription, nuclear entry and integration, nuclear export, 
budding and maturation (Fig I.1). 
Binding and Entry 
HIV-1 infects cells of the immune system, mainly CD4+ T-cells, macrophages, and 
dentritic cells.  The virus initiates binding through the interaction of its trimeric envelope 
complex (gp 160 spike) with the host cell receptor, CD4, a protein important for normal 
immune recognition (Dalgleish et al., 1984; Sattentau et al., 1993).  The gp160 protein 
consists of a transmembrane domain (TM or gp41) and a surface domain (SU or gp120).  
gp120 attaches to CD4  receptor with high affinity, however this binding is insufficient 
for infection, which requires one of several chemokine receptors including CCR5 and 
7 
 
Figure I.1 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug 
Discovery, Vol. 6, Flexner, HIV drug development – the next 25 years, 959-966, 2007. 
8 
 
Figure I.1.  HIV-1 Life Cycle.  The virus first interacts with a CD4+ receptor and a 
chemokine co-receptor through its envelope glycoprotein (entry).  After binding, the 
viral core is released into the host cell, uncoated, and reverse-transcribed into the viral 
cDNA (reverse transcription).  The viral cDNA is then transported to the nucleus and 
integrated into the host cell genome (integration).  After transcription, viral mRNAs are 
transported to the cytoplasm and translated into the viral proteins (nuclear export).  The 
structural proteins and enzymes are transported to the site of budding at the plasma 
membrane (budding).  During or after budding, HIV-1 protease cleaves Gag and Gag-
Pol polyproteins, leading to a infectious and mature virion (maturation).  Proteins in 
green boxes are currently targeted by anti-viral drugs, yellow boxes indicate targets in 
clinical trials, and red boxes indicate potential drug targets (Pham et al., 2007). 
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CXCR4 (Clapham and Weiss, 1997).  On binding of gp120 to CD4 receptor, 
conformational changes occur that allow the chemokine binding domains of gp120 to 
interact with either CCR5 or CXCR4 (Ugolini et al., 1997).  This interaction results in 
structural rearrangements that allow gp41 to penetrate the cell membrane (Gallo, Puri, 
and Blumenthal, 2001).  HR1 and HR2 repeat sequences within gp41 interact to collapse 
the extracellular part of gp41, bringing the viral and cell membranes in close proximity 
(Chan and Kim, 1998; Wyatt and Sodroski, 1998).  The resulting fusion of viral and cell 
membranes allows the virus to enter the host cell (Wyatt and Sodroski, 1998). 
Uncoating and Reverse Transcription 
After fusion of the viral and host membranes, the viral core enters the host cytoplasm and 
undergoes a poorly understood process called uncoating, during which it forms the 
reverse transcription complex.  Reverse transcription is mediated by the viral reverse 
transcriptase (RT), which has both RNA-dependent and DNA-dependent DNA 
polymerase activities (Yarchoan et al., 1985).  RT also has a ribonuclease H (RNAse H) 
domain that degrades the RNA from the RNA-DNA hybrids formed during the reaction 
(Chandra, Gerber, and Chandra, 1986).  Reverse transcription yields a double stranded 
viral cDNA that is then ready for integration into the host genome (Yarchoan et al., 
1985).  Due to its very essential role, RT was one of the first targets for anti-retroviral 
drugs and continues to play an important role in anti-HIV therapy (Broder et al., 1985; 
Castro et al., 2006; Frankel and Young, 1998). 
10 
 
HIV-1 RT lacks a proofreading mechanism, which causes transcription to be very error 
prone, leading to a large number of mutations in the newly synthesized cDNA.  
Additionally, HIV-1 has two copies each of its genomic RNA and because the RT binds 
to the genomic RNA template with relatively low affinity, transcription jumps from one 
strand to another resulting in a recombinant DNA genome derived from both parental 
RNA strands.  As a result of these two factors, viral populations in an individual are 
highly variable forming quasi-species.  Thus HIV can rapidly evolve to evade host 
immune responses and to develop resistance to antiretroviral therapies (Castro et al., 
2006). 
Nuclear Import and Integration 
The newly synthesized viral cDNA is then transported to the nucleus as a nucleoprotein 
complex called the pre-integration complex (PIC).  Integrase forms an important part of 
this complex and some studies have detected the presence of nucleocapsid, matrix as well 
as the accessory protein, Vpr (Bukrinsky et al., 1993; Gallay et al., 1995a; Gallay et al., 
1995b).  Vpr and integrase have been shown to play a role in the nuclear import of the 
PIC (Zhang et al., 2001) along with other cellular proteins like importin-α and 
nucleoporins.  Once in the nucleus, integrase catalyzes the integration of the viral cDNA 
into the host genome.  After integration, the provirus acts as a template for transcription 
and synthesis of viral mRNAs, a process that requires the viral transcriptional 
transactivator protein, Tat (Parada and Roeder, 1996).  The viral mRNAs are unspliced 
(coding for Gag and GagPol polyprotein precursors and are encapsulated as genomic 
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RNA into the budding virions), partially spliced (coding for Env, Vif, Vpu and Vpr 
proteins) and highly spliced (coding for Rev, Tat and Nef proteins) (Castro et al., 2006; 
Emerman and Malim, 1998; Frankel and Young, 1998). 
Nuclear Export  
The spliced and unspliced mRNAs are exported into the cytoplasm where they are then 
translated into viral proteins.  Cellular mRNAs are fully spliced before being transported 
to the cytoplasm.  Partially spliced mRNAs of HIV-1 are transported with the help of the 
viral protein Rev, which binds the Rev response element (RRE) within the unspliced viral 
mRNAs (Emerman and Malim, 1998; Frankel and Young, 1998). 
Viral Assembly 
After their export from the nucleus, the viral mRNAs are translated into the full 
complement of viral proteins.  The Gag and GagPol precursor polyproteins give rise to 
structural proteins that form the viral core and viral enzymes, respectively, and play an 
important role in assembly.  The matrix domain of Gag is co-translationally myristolated 
and is responsible for targeting and binding the plasma membrane (Bryant and Ratner, 
1990; Facke et al., 1993).  Two copies of single-stranded genomic RNA are then 
encapsidated, mediated by interactions between the packaging signal and the 
nucleocapsid (Clever and Parslow, 1997; Laughrea et al., 1997).  Following 
encapsidation, interactions between Gag nucleocapsid and RNA lead to alignment and 
packing of Gag molecules.  The capsid protein has also been shown to play a role in viral 
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assembly (Gamble et al., 1997).  HIV-1 envelope protein precursor, gp160, is synthesized 
in the endoplasmic reticulum.  During its transport through the Golgi apparatus, gp 160 is 
cleaved by host proteases to generate the mature envelope proteins, gp120 and gp41 
(Chan et al., 1997; Earl, Moss, and Doms, 1991).  These envelope glycoprotein 
complexes are rapidly incorporated into viral particles through their interactions with the 
matrix domain of Gag (Frankel and Young, 1998).  
Budding and maturation 
During budding, the structural proteins, enzymes and encapsidated RNA genome pinch 
off from the host membrane by a process known as budding to give rise to an immature 
and a non-infectious viral particle.  During or shortly after budding, the viral protease 
cleaves Gag and Gag-Pol polyproteins in a specific, sequential manner, producing mature 
and functional structural proteins and enzymes (Kohl et al., 1988).  This protease-
mediated cleavage results in significant structural rearrangements of viral proteins and 
formation of a cone-shaped core, leading to maturation of the viral particle.  Because 
protease is essential for viral maturation, it is one of the most important targets for 
antiretroviral therapy.  However, resistance to one or more protease inhibitors has 
lowered the efficacy of these drugs and will be discussed in detail in subsequent sections. 
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HIV-1 PROTEASE 
HIV-1 protease, encoded by the pol gene, plays a pivotal role in the viral life cycle.  The 
protease cleaves Gag and GagPol precursor polyproteins into fully functional enzymes 
and structural proteins, thus playing an essential role in viral maturation (Kohl et al., 
1988) (Fig I.2).  Mutations that inactivate the protease prevent viral maturation, resulting 
in a non-infectious viral article (Kramer et al., 1986).  Due to its crucial role in the viral 
life cycle HIV-1 protease is an important target for anti-retroviral therapy (Kramer et al., 
1986). 
Structure, Mechanism of Action and Function 
HIV-1 protease is an aspartyl protease that has the conserved Asp-Thr-Gly sequence as in 
the case of other retroviral proteases (Seelmeier et al., 1988).  This enzyme has 99 amino 
acids and functions as a homodimer where the Asp-Thr-Gly triad from each monomer 
contributes to a single active site (Navia et al., 1989; Wlodawer et al., 1989) that is 
symmetric in the unliganded state.  The protease has four main structural regions: the 
active site (residues 23-28, 81-84), the flap region (residues 40-60), the dimer interface 
(residues 1-10, 90-99) and the core of each monomer (residues 11-22, 29-39, 61-80, 85-
90).  The two aspartyl residues present at the base of the active site are essential for 
catalysis.  HIV-1 protease catalyzes hydrolysis of peptide bonds by using an activated 
water molecule to catalyze nucleophilic attack of the carbonyl group of the scissile amide 
bond (Navia et al., 1989).  The flaps form the roof of the active site and play an 
14 
 
Figure I.2 
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Figure I.2:  Structure of HIV-1 Protease.  (A.) Structure of HIV-1 protease complexed 
to a substrate.  The two monomers are shown in cyan and magenta, and the catalytic 
aspartates are shown in yellow.  In green is the substrate peptide.  
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important role in substrate binding.  The substrate cleavage sites thread through the active 
site in an extended manner. 
As mentioned previously, Gag and GagPol polyproteins give rise to HIV-1 structural 
proteins and viral enzymes.  The translated polyproteins are targeted and bound to the 
inner surface of the plasma membrane.  The rest of the viral particle is assembled and the 
new immature viruses are released from the host cell via budding.  During or after 
budding, the HIV-1 protease cleaves at least ten different sites within Gag and GagPol 
polyproteins giving rise to the structural proteins, matrix (MA), capsid (CA), 
nucleocapsid (NC) and p6; the viral enzymes, protease (PR), reverse transcriptase (RT) 
and integrase; and two small spacer peptides, p1 and p2 (Fig I.3) (Kohl et al., 1988).  This 
proteolytic processing of Gag and GagPol leads to the formation of mature viral particles 
that are now infectious (Kramer et al., 1986). 
Proteolytic processing of Gag and GagPol is a sequential and highly ordered process 
(Pettit et al., 1994a; Wiegers et al., 1998).  The order of cleavage within Gag has been 
shown to be very specific and is important for fitness/infectivity (Pettit et al., 2002; Pettit 
et al., 1998).  The first site to be processed is the CA-p2 cleavage site, with the remaining 
sites processed as shown in (Fig I.4).  Though the exact mechanism of Gag processing is 
not understood, studies have shown that several factors play a role in determining the 
order of cleavage, including the cleavage site sequence, presence of spacer domains and 
the interactions with RNA (Feher et al., 2002; Pettit et al., 2002; Pettit et al., 1994b; 
Sheng et al., 1997). 
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Figure I.3. 
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Figure I.3.  Schematic Representation of HIV-1 Genome and Organization of Gag 
and GagPol Polyproteins.
19 
 
Figure I.4. 
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Figure I.4.  A Schematic Overview of the Sequential Proteolytic Processing of HIV-1 
Gag Polyprotein.
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Substrate Recognition, Binding and Cleavage 
HIV-1 protease recognizes and cleaves Gag and Gag-Pol polyproteins at least ten 
different sites resulting in fully functional viral proteins (Fig I.3).  The flaps of the 
protease close down on the active site forming a tunnel through which the substrates are 
threaded.  The specific amino acids in the P4 to P3' positions of the substrate around the 
scissile bond are essential for substrate recognition (Tözsér et al., 1991a; Weber et al., 
1989).  The corresponding binding sites within the enzyme include seven sites, S4 
through S3'.  Though the protease has been shown to cleave peptides as short as 6 amino 
acids, efficient processing occurs when the peptide is seven or more residues 
longer(Griffiths et al., 1992; Tözsér et al., 1991b).  Amino acids outside the cleavage site, 
and the context of cleavage sites within the Gag or Gag-Pol polyprotein can influence the 
rates of cleavage at various sites (Griffiths et al., 1992; Kohl et al., 1988; Tözsér et al., 
1991a). 
Analysis of Gag cleavage sites from a number of retroviruses showed patterns of amino 
acid preferences that could broadly be classified into Type 1 and Type 2 cleavage sites 
(Pettit et al., 1991).  Type 1 sites had Pro in their P1' sites whereas Type 2 had Ala, Val 
or Leu.  These two classes also had distinct differences in the flanking amino acids.  Type 
1 sites were also observed to have a small amino acid at P4, uncharged residues at P3 
with Gln observed occasionally and aliphatic amino acids at P2 or Asn.  P1 had Tyr, Phe 
or Leu and P2' had aliphatic residues.  Type 2 sites had small amino acids at the P4 
position similar to Type 1.  P3 amino acids were uncharged with the exception of an 
22 
 
occasional Arg or Lys.  P2 had aliphatic residues like the Type 1, however Leu was most 
frequent at P1 unlike Type 1 sites.  P2' and P3' were aliphatic with Ile excluded from P2' 
and Ala favored at P3'.  However, despite other studies to determine and characterize 
sub-site amino acid preferences, substrate recognition was still poorly understood. 
As described in the preceding section, amino acid preferences at the different sites within 
the cleavage site sequences were known, but how these ten highly variable cleavage site 
sequences were recognized by the protease was still not understood.  From Fig I.5 it is 
evident that the various cleavage site sequences are non-homologous and asymmetric in 
both charge and size.  These characteristics begged the question as to how a symmetric 
protease could recognize and cleave an asymmetric substrate.  Structural studies from the 
Schiffer lab have shown that the various cleavage site peptides adopt a conserved 
shape/volume, which was hypothesized as the basis for recognition of substrate sites by 
the HIV-1 protease (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002).  The overlapping 
volume of four or more of the substrates within the active site of the protease defines the 
conserved shape or the “substrate envelope” (Fig1.6).  The P1-P3 region forms a toroid, 
which is thought to be important for specificity, whereas the numerous backbone-to-
backbone interactions facilitate binding (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002).  
The substrate envelope not only explains specificity but also has significant implications 
for the development of resistance to various protease inhibitors and substrate co-
evolution.
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Figure I.5. 
 
                          
Cleavage site Amino acid sequence 
Gag P5 P4 P3 P2 P1 / P1' P2' P3' P4' P5' Gag amino acid positions 
MA/CA V S Q N Y / P I V Q N 128-137 
CA/p2 K A R V L / A E A M S 359-368 
p2/NC S A T I M / M Q R G N 373-382 
NC/p1 E R Q A N / F L G K I 428-437 
p1/p6gag R P G N F / L Q S R P 444-453 
             
Pol P5 P4 P3 P2 P1 / P1' P2' P3' P4' P5'  
NC/TFP E R Q A N / F F R E D  
TFP/p6pol E D L A F / L Q G K A  
p6pol/PR V S F N F / P Q I T L  
PR/RT C T L N F / P I S P I  
RT(p51)/RT(p15) G A E T F / Y V D G A  
RT/IN I R K V L / F L D G I   
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Figure I.5.  HIV-1 Protease Cleavage Site Sequences.   These are based on the HXB2 sequence.  Slashes indicate the site 
where the proteeolytic cleavage occurs (MA:matrix, CA:capsid, NC:nucleocapsid, TFP:transframe protein, 
PR:protease,RT:reverse transcriptase, IN:integrase).
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Figure I.6 
 
 
Reprinted from Structure, Vol. 10, Prabu-Jeyabalan, Nalivaika, and Schiffer.  Substrate 
shape determines specificity of recognition for HIV-1 protease: analysis of crystal 
structures of six substrate complexes, 369-381, 2002 with permission from Elsevier.
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Figure I.6:  The Substrate envelope.  In blue is the consensus volume occupied by at 
least four out of six cleavage site peptides when bound to the D25N inactive HIV-1 
protease.  The six peptides are shown in the same superposition within the consensus 
volume. 
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PROTEASE INHIBITORS AND RESISTANCE  
The earliest indications for a critical role of the protease in the HIV-1 life cycle were 
mutational studies that inactivated the protease, generating non-infectious viral particles 
(Kohl et al., 1988).  Further studies led to the development of various types of molecules 
that bind within the active site of the protease, inhibiting its activity and leading to loss of 
viral infectivity.  Structural studies of HIV-1 protease in combination with these initial 
inhibitor molecules led to design several clinically successful protease inhibitors that 
have significantly slowed the progress of HIV-1 infection and delayed the onset of AIDS. 
Protease inhibitor design is based on peptidomimetics that target the fact that the protease 
was an aspartyl protease.  Currently, nine Protease inhibitors are being used in the clinic: 
ritonavir (RTV), saquinavir (SQV), lopinavir (LPV), indinavir (IDV), nelfinavir (NFV), 
(fos)amprenavir (APV), atazanavir (ATV), darunavir (DRV), and tipranavir (TPV) (Craig 
et al., 1991; Kempf et al., 1995; Partaledis et al., 1995; Patick et al., 1996; Robinson et 
al., 2000) (Sham et al., 1998; Turner et al., 1998; Vacca et al., 1994).  Except for TPV, all 
mimic the natural substrates of the protease and bind competitively within its active site.  
These peptidomimetic inhibitors have a hydroxyl group at a position equivalent to the 
scissile bond in the natural cleavage sites.  The hydroxyl group displaces the active site 
water and interacts with the active site aspartates, mimicking the transition state.  These 
inhibitors are much shorter than the substrate peptide sequence required for recognition 
and cleavage.  In addition, they have large hydrophobic groups surrounding the hydroxyl 
group, which form backbone interactions with the protease as well as van der Waals 
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interactions with residues in the protease sub sites.  Together, these interactions enable 
the protease inhibitors to bind within the active site of HIV-1 protease with high 
specificity and affinity.  
Unfortunately, the efficacy of all protease inhibitors used in the clinic has been quickly 
reduced by the emergence of resistance.  Currently, protease inhibitors are combined with 
other types of antiretroviral drugs as a part of HAART.  Though initially successful in 
suppressing the virus, the resulting resistance to the various drugs has led to ineffective 
therapy.  The emergence of highly evolved resistant viruses is due to several factors, 
including the high replication rate of HIV-1, and lack of a proofreading mechanism by 
the RT.  Resistance to protease inhibitors is a very complex process, in which initial 
mutations arise within the protease gene, but with continued therapy the virus evolves to 
acquire multiple mutations both within the protease and other regions of the HIV-1 
genome (Condra et al., 1995; Kaplan et al., 1994; Kaplan et al., 1993; Molla et al., 1996). 
Evolution of Protease Resistance 
Viral populations in HIV-1 infected individuals exist as complex and dynamic mixtures 
of mutant genomes, referred to as quasi-species, with usually one species dominating as 
result of being the fittest (Domingo and Holland, 1997; Eigen, 1993).  Protease inhibitor 
therapy suppresses viral replication and infectivity resulting in the emergence of other 
viral species that are more fit.  Thus, the selective pressure of protease inhibitor therapy 
results in a wide spectrum of amino acid substitutions within the protease that is 
advantageous to the virus. 
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Under protease inhibitor therapy, a majority of initial mutations arise within the active 
site of the enzyme, directly affecting inhibitor binding and are the primary cause of 
resistance to protease inhibitors.  Typical primary mutations include D30N, G48V, 
I50L/V, V82A/F/T, I84V and L90M (Gulnik et al., 1995), some of which have been 
investigated in my dissertation research.  Several primary PI resistance mutations have 
been described that are a signature of particular protease inhibitors.  For example, 
patients failing NFV therapy develop the D30N protease mutation (Patick et al., 1998), 
while the I50V and I50L mutations are selected in patients failing amprenavir and 
atazanavir therapy, respectively (Colonno et al., 2004; Mahalingam et al., 1999).  
Mutations at protease residue 82 are observed in patients treated with RTV and SQV, and 
the G48V mutation results in resistance to SQV and ATV(Deeks et al., 1998; Molla et al., 
1996).  The I84V mutation is one of the most severe primary resistance mutations as it 
causes cross-resistance to most protease inhibitors (Zolopa et al., 1999).  Thus, a range of 
primary resistance mutations are selected, some of which are unique to a single protease 
inhibitors, whereas others confer resistance to two or more protease inhibitors.  
Subsequent to the primary mutations, additional mutations arise that further reduce 
sensitivity to protease inhibitors.  These secondary mutations are often located distant 
from the active site, although the mechanism by which they enhance resistance is poorly 
understood.   
Primary and secondary protease mutations provide a selective advantage to HIV-1 virus 
by significantly reducing its susceptibility to protease inhibitors.  However, these 
mutations lower the catalytic activity of the viral protease (Gulnik et al., 1995).  Reduced 
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protease efficacy not only disrupts Gag and GagPol processing as demonstrated by the 
accumulation of partially cleaved products, but also results in loss of viral fitness as 
shown by reduced replicative capacities (Croteau et al., 1997; Mahalingam et al., 1999; 
Nijhuis et al., 1999; Zennou et al., 1998).  With prolonged protease inhibitor therapy, 
however, mutations emerge that compensate for the deleterious effects of primary and 
secondary mutations in several ways.  One way is that compensatory mutations 
accumulate within the protease and improve viral fitness by mechanisms that are not well 
understood (Mammano et al., 2000; Martinez-Picado et al., 1999).  Conformational 
changes in the protease as a result of these mutations likely allow the protease to maintain 
adequate function even as it maintains resistance to inhibitors (King et al., 2004; Prabu-
Jeyabalan et al., 2003).  Examples of compensatory mutations that have been clearly 
shown to improve viral fitness are L10I, L63P and A71V (Mammano et al., 2000; 
Martinez-Picado et al., 1999; Perrin and Mammano, 2003).  However, several other 
mutations arise, and it is not known if they are solely compensatory or if they only 
contribute to enhance resistance.  It is likely that some of these mutations actually 
contribute to both improvements in viral fitness compensatory and resistance.  
Co-evolution of protease cleavage sites 
Due to inefficient Gag and GagPol processing compensatory mutations also develop 
within the substrate cleavage sites following accumulation of resistance mutations within 
the protease (Doyon et al., 1996; Zhang et al., 1997).  Substrate mutations were first 
reported within the NC-p1 and p1-p6 cleavage sites.  The A431V mutation within the 
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NC-p1 cleavage site and L449F in the p1-p6 cleavage site selected during the evolution 
of protease inhibitor resistance were observed to correlate with V82A and I50V protease 
resistance mutations, respectively (Maguire et al., 2002; Zhang et al., 1997).  These 
cleavage site mutations have been demonstrated to be compensatory in nature by 
improving replicative capacity/processing (Feher et al., 2002; Prabu-Jeyabalan et al., 
2004).  Other cleavage site mutations, including I437V and P453R, have now been well 
documented and are associated with several major protease resistance mutations 
(Maguire et al., 2002; Nijhuis et al., 1999), suggesting that with prolonged protease 
inhibitor therapy, evolution of protease cleavage sites could be a fairly frequent 
mechanism for maintaining viral fitness even as the virus evolves resistance to protease 
inhibitors.   
Indeed, Gag processing has been shown to be enhanced by the A431V and I437V 
mutations within the NC-p1 cleavage site (Dam et al., 2009; Feher et al., 2002).  In fact, 
there were clear structural changes that increased binding of the A431V NC-p1 site with 
the V82A protease (Prabu-Jeyabalan et al., 2004).  Recently though, both A431V and 
I437V have been shown directly increase resistance, possibly as a result of this enhanced 
Gag processing (Dam et al., 2009; Nijhuis et al., 2007).  Similarly, the L449F mutation 
within the p1-p6 cleavage site has been shown to increase processing at this cleavage site 
(Feher et al., 2002; Kolli, Lastere, and Schiffer, 2006; Maguire et al., 2002).  Structural 
modeling studies have observed that the change from a smaller amino acid to a larger Phe 
likely improves van der Waals contacts contributing improved Gag processing (Kolli, 
Lastere, and Schiffer, 2006).  This suggests a likely mechanism whereby decreased 
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interactions between cleavage sites and mutant protease can be offset by compensatory 
mutations within the cleavage sites leading to improved binding and processing.  
Drug Resistance – A change in molecular recognition 
The development of drug resistance is a major factor for the failure of protease inhibitor 
therapy.  As described previously, the virus evolves to accumulate a multitude of 
mutations within the protease that prevent protease inhibitors from binding to the 
protease.  More than half the residues within the protease mutate in different 
combinations and lead to drug resistance.  Thus the protease is very plastic which raises 
the question as to how it continues to recognize and cleave its substrates while preventing 
the inhibitor from binding.  Structural studies from the Schiffer lab have shown that most 
of the protease inhibitors occupy a similar volume and contact similar resides within the 
active site of the protease (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002) (Fig I.7).  It 
has been demonstrated that most of the primary resistance associated mutations within 
the active site of the protease occur at sites where inhibitor atoms contact protease 
residues beyond the substrate envelope and are thus more important for inhibitor binding 
than substrate recognition (King et al., 2004; Prabu-Jeyabalan et al., 2006).  King et al., 
(King et al., 2004) also suggested that if, however, the substrate atoms contact the very 
same residues in the active site of the protease, this could lead to impaired recognition 
and cleavage of the substrates leading to the evolution of compensatory mutations within 
the protease cleavage sites.  These studies have led to design of inhibitors that fit well 
within the substrate envelope and contact the same residues within the protease that are 
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Figure I.7. 
 
 
Reprinted from Chemistry and Biology, Vol. 11.  King, N. et al., Combating 
susceptibility to drug resistance: lessons from HIV-1 protease, 1333-1338, 2004 with 
permission from Elsevier. 
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Figure I.7:  Substrate and Inhibitor Envelopes of HIV-1 Protease.  (A) Substrate 
envelope in blue with the six substrate peptides superposed.  (B) Top view of the 
substrate envelope within the active site of the protease.  (C) Inhibitor envelope in red, 
calculated from the overlapping volume of five or more of the inhibitor complexes with 
active HIV-1 protease.  (D) Top view of the inhibitor envelope within the active site of 
the protease.  (E) Superposition of the substrate envelope and inhibitor envelope.  Also 
shown are residues contacted by the inhibitor atoms that mutate to cause drug resistance.
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required for substrate recognition.  Such inhibitors may be more successful in preventing 
drug resistance, as the likelihood of several substrates co-evolving simultaneously is 
lower.  
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Scope of the thesis 
Drug resistance is a major obstacle for the success of protease inhibitors in combating 
HIV-1 infections.  Investigating the evolution of resistance to protease inhibitors, 
including substrate co-evolution, would give insights into the molecular mechanisms 
underlying drug resistance and lead to design of more robust protease inhibitors.  
Substrate co-evolution is becoming increasingly common, especially in the NC-p1 and 
p1p6 sites.  Many of these mutations improve viral fitness by enhancing Gag processing.  
Also, some mutations within Gag cleavage site co-evolve to directly enhance resistance. 
An in depth study of co-evolution would help identify correlating mutations in the 
cleavage sites and the protease.  The impact of this correlation on viral fitness and drug 
susceptibility would give insights into the evolution of drug resistance.  Such a study 
would have direct implications for evaluating patients failing protease inhibitor therapy 
and formulating treatment.  X-ray crystallographic studies to study structural changes in 
the protease as well as the co-evolving substrate peptide will give valuable insights into 
co-evolution and the underlying mechanisms for drug resistance, leading to design of 
more robust protease inhibitors. 
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CHAPTER II 
CO-EVOLUTION OF NELFINAVIR-RESISTANT HIV-1 
PROTEASE AND THE p1–p6 SUBSTRATE 
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The work presented in the following chapter was a collaborative effort.  The viral RNA 
was extracted and sequenced by Stephane Lastere, I designed and performed the analyses 
and Celia Schiffer and I wrote the paper. 
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ABSTRACT 
The selective pressure of the competitive protease inhibitors causes both HIV-1 protease 
and occasionally its substrates to evolve drug resistance.  We hypothesize that this occurs 
particularly in substrates that protrude beyond the substrate envelope and contact residues 
that mutate in response to a particular protease inhibitor.  To validate this hypothesis we 
analyzed substrate and protease sequences for covariation.  Using the Chi-Square test we 
show a positive correlation between the nelfinavir-resistant D30N/N88D protease 
mutations and mutations at the p1-p6 cleavage site as compared to the other cleavage 
sites.  Both nelfinavir and the substrate p1-p6 protrude beyond the substrate envelope and 
contact residue 30, thus possibly making the p1-p6 cleavage site more vulnerable to co-
evolution. 
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INTRODUCTION 
HIV-1 protease inhibitors bind competitively to the active site of the enzyme (Wlodawer 
and Erickson, 1993).  Mutations in the protease that alter inhibitor binding and cause drug 
resistance can also affect substrate recognition by changing the enzyme’s substrate 
specificity.  To compensate, the virus will be under selective pressure to co-evolve the 
substrate sequence, thereby allowing the protease to retain activity (Bally et al., 2000; 
Doyon et al., 1996; Mammano et al, 1998; Feher et al., 2000).  Earlier studies from our 
laboratory have shown that substrate specificity of the protease is based on the shape 
adopted by the substrate sequences, defined as “the substrate envelope” (Prabu-Jeyabalan 
et al, 2002). Most primary active-site mutations occur outside the substrate envelope and 
thereby preferentially impact inhibitor binding over substrate recognition.  Therefore 
most of the substrates do not co-evolve with the protease.  However, some substrates 
protrude beyond the envelope and we observe that they are the ones that co-evolve with 
the protease. 
In this study, we focus on the D30N and N88D protease mutations, which are a signature 
of nelfinavir (NFV) resistance (Pai and Nahata, 1999; Patick et al., 1998) and their 
correlation with mutations at the p1-p6 substrate cleavage site.  In the crystal structure of 
wild-type (WT) HIV-1 protease in complex with NFV, Asp30 forms a hydrogen bond 
with the m-phenol group of NFV (Kaldor et al., 1997) and superposition of NFV on the 
substrate envelope shows that this group protrudes from the envelope (Fig II.1a), 
suggesting that mutation at this residue will preferentially impact inhibitor binding over  
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Figure II.1 
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Figure II.1:  NFV and p1-p6 both contact D30 outside the substrate envelope.  a) 
Shown in top and bottom views is NFV in red within the substrate envelope in blue.  The 
m-phenol group of NFV protrudes to contact D30 of monomer a (D30a) outside the 
substrate envelope b) p1-p6 in green within the substrate envelope.  GlnP2′ protrudes 
from the envelope and interacts with D30 of monomer b (D30b).
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substrate recognition.  The D30N mutation of aspartic acid to an asparagine in the 
protease likely results in a weaker hydrogen bond that destabilizes NFV binding.  In this 
study we present an analysis of Gag and Pol sequences from viral isolates of patients 
treated with protease inhibitors that reveals correlations between the D30N/N88D 
protease mutations and mutations within the corresponding p1-p6 cleavage site, which 
also makes direct ionic interactions with Asp30. 
SEQUENCE ANALYSIS  
Viral sequences (N=196) extending from Gag aa 346 to Pol aa 162 were obtained from 
patients who were part of the NARVAL trial (Meynard et al., 2002).  These patients, 
treated with highly active antiretroviral therapy, had received a median of 3 prescribed 
protease inhibitors, for an average of 32 months.  Plasma viral RNA was extracted and 
nested RT-PCR was performed to amplify the gag-protease region, including p2, p7, p1, 
p6 and the whole PR.  Direct dideoxynucleoside terminator cycle sequencing of the PCR 
product was performed and sequencing products were analyzed on an ABI 3100 (Perkin 
Elmer ABI, Foster City, Calif., USA) instrument, and manually proof read and edited 
using Sequence Navigator software, in both 5′ and 3′ directions.  Polymorphisms were 
defined as differences in amino acid usage with respect to the HIV-1 B subtype 
consensus sequence (Los Alamos HIV database, http://hiv-web.lanl.gov).  When a 
mixture of wild-type and mutant residues was detected, the corresponding codon was 
classified as mutated.  Over 90% of these isolates were subtype B.  The viral sequences, 
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which included the protease and 10 substrate cleavage sites, had a median of 6 protease 
mutations per sequence.   
The entire data set was read and entered into a Microsoft Access Database using software 
written in Visual Basic.  Our analysis focused on qualitative changes in cleavage-site 
sequences, as compared to the consensus HXB2 sequence, that covary with the 
D30N/N88D drug-resistant substitutions in the protease.  For each peptide sequence with 
the D30N/N88D substitutions in the enzyme, the corresponding substrate cleavage sites 
were scored for the presence or absence of mutations.  Conversely, for every substrate 
site that scored positive for amino acid substitutions, changes at positions 30 and 88 in 
the enzyme were scored and tabulated.   
The simultaneous occurrence of cleavage-site mutations and the D30N/N88D protease 
mutations were compared for each of the seven substrates studied (Fig II.2).  The 
percentage of mutated substrate sequences that occurred with the D30N/N88D mutations 
in the corresponding protease sequence was calculated by dividing the number of mutated 
cleavage-site sequences by the total number of protease sequences with D30N/N88D 
mutations (N=21).  The percentage of mutated substrate sequences that did not occur with 
corresponding D30N/N88D protease mutations was calculated by dividing the number of 
mutated cleavage-site mutations by the total number of protease sequences without 
D30N/N88D mutations (N=175).  The Chi-Square test of significance (after applying the 
Yates correction) was performed to test for correlation between cleavage-site mutations 
and the D30N/N88D protease mutations (Table II.1).  Statistically significant correlations 
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Figure II.2 
54 
Figure II.2:  Mutation Rates at Substrate Cleavage Sites with and without 
Corresponding D30N/N88D Protease Mutations.  Green bars indicate the simultaneous 
occurrence of cleavage-site mutations and the D30N/N88D protease mutations.  Yellow 
bars represent percentages of isolates in which mutations occur in the cleavage sites in 
the absence of the D30N/N88D protease mutations.
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Table II.1 
Substrate 
Cleavage Site 
Number of Mutated 
Cleavage-Site 
Sequencesa 
χ2 P value Phi correlation 
coefficient 
CA-p2 27 0.07 0.79 +0.01 
p2-NC 175 2.13 0.14 -0.13 
NC-p1 86 6.83 0.01 -0.2 
p1-p6 74 10.18 0.001 +0.24 
Tf-Pr 184 0.01 0.92 +0.03 
Auto-Pr 5 0.16 0.16 +0.15 
Pr-RT 16 0.03 0.86 -0.04 
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Table II.1:  Covariation Between Substrate Mutations and D30N/N88D Protease 
Mutations 
Total number of viral sequences isolated from patients = 196 
Total number of viral sequences with D30N/N88D protease mutations = 21 
Total number of viral sequences without D30N/N88D protease mutations = 175
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were those that had p values ≤ 0.05.  In addition the phi correlation coefficient was 
calculated to determine positive or negative correlations.   
Substitutions were observed in all 7 substrate sites studied.  Initial analysis of the 
sequences indicated that some substrate cleavage sites are more prone to mutations than 
others.  Among the sequences analyzed, the mutation rates of p2-NC (90.8%) and TF-PR 
(90.8%) were much higher than those of the CA-p2 (6.8%) and AutoPr (3.4%) cleavage 
sites, which were almost immutable.  We then examined all substrate cleavage sites and 
the corresponding protease sequences for mutations and covariations. 
p1–p6 CLEAVAGE SITE   
D30N/N88D and p1-p6 substrate site mutations were observed to be significantly 
correlated (Χ2=10.18, p=0.0014) and the phi value indicates a positive correlation as 
shown in Table II.1.  The majority of isolates with the D30N/N88D protease mutations 
(71%) also had mutations in the p1-p6 cleavage site.  Conversely, only 33% of the 
corresponding p1-p6 cleavage sites had mutated in the absence of D30N/N88D protease 
mutations (Fig II.2).  There were ten protease sequences that had only D30N, and only 
two had mutations in the corresponding p1-p6 cleavage site.  Most likely, these viruses 
did not have sufficient time or selective pressure to evolve either the N88D protease 
mutation or the p1-p6 mutations.  Thus, the combined D30N/N88D substitutions in the 
protease covary with mutations in the p1-p6 substrate.   
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To examine the possible effects of the D30N mutation on protease recognition and 
cleavage of p1-p6, structural modeling studies were performed.  Asp30 in the active site 
of WT HIV-1 protease plays an important role in recognizing and binding this particular 
substrate cleavage site.  Asp30 is one of four protease residues that form direct side-chain 
hydrogen bonds with substrate peptides.  Asp30 forms one interaction with substrates 
sequences MA-CA, CA-p2 and p2-NC but forms three interactions with p1-p6 (Prabu-
Jeyabalan et al, 2002).  Specifically, Asp30′ OD2 makes a hydrogen bond with GlnP2′ 
NE2 and ArgP4′ NE of the p1-p6 substrate peptide and Asp30′ OD1 makes a salt bridge 
with ArgP4′ NE (Fig II.3a).  The interactions of p1-p6 with Asp30 are located where this 
substrate protrudes from the substrate envelope (Fig II.1b) indicating a region in this 
particular substrate that could be affected by a resistant mutation and thereby propagates 
co-evolution.  Under the selective pressure of NFV, Asp30 mutates to an Asn.  Modeling 
in the D30N substitution suggests that some of these interactions may be altered (Fig 
II.3b).  The salt bridge between Asp30′ in the WT protease and ArgP4′ in p1-p6 may be 
weakened to a hydrogen bond with Asn, however, in the other substrates that the 
interactions with Asp30 are unlikely to be modified with the D30N substitution.  It is 
therefore likely that Asp30′ is more crucial to the recognition of the p1-p6 substrate site 
than to other cleavage sites.  Therefore, the D30N protease substitution is more likely to 
select for compensatory mutations within the p1-p6 substrate cleavage site than with 
other substrate cleavage sites. 
The above observations led us to examine the specific substitutions within the p1-p6 
cleavage site.  In Table II.2 we present a matrix of the mutational pattern to examine 
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Figure II.3 
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Figure II.3:  Modeling Studies of Complexes of HIV-1 Protease Variants and the p1-
p6 Substrate.  The two protease monomers are shown in cyan and magenta and the p1-
p6 peptide in green, in red is oxygen and in blue is nitrogen. Hydrogen bonds are shown 
as dashed black lines.  The figures were made with the graphics progam MIDAS (Ferrin 
et al., 1988).  a) Crystal structure of HIV (D25N) protease complexed with the p1-p6 
substrate peptide (Prabu-Jeyabalan et al, 2002). van der Waals radii are shown for 
residues 8a, 29a-b, 30a-b, 81a, 82a, 84a, P1′, P2′, P3′ and P4′.  Hydrogen bonds between 
D30b and GlnP2′ and ArgP4′ are shown.  b) Probable contacts and hydrogen bonds made 
by N30b are shown.  c) Likely contacts made by AsnP3′ (wt SerP3′) with van der Waals 
radii shown for residues around it.  Also shown are the probable hydrogen bonds d) 
Probable contacts made by PheP1′ (wt LeuP1′) with van der Waals radii of the 
surrounding residues.  e) van der Waals radii are shown for contacts that are likely made 
when both P1′ and P3′ are mutated. 
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Table II.2:  
Amino 
Acid 
P G N F L Q S R 
Substrate  
Subsite 
P4 P3 P2 P1 P1′ P2′ P3′ P4′ 
P4         
P3         
P2   3%(D,I)      
P1         
P1′     47%(F)    
P2′      1%   
P3′     5%  34%(N,T)  
P4′     1%  3% 5%(S) 
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Table II.2:  Frequency of Mutations in the p1-p6 Substrate Cleavage Site.
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whether multiple sites within the substrate mutate simultaneously.  Almost no mutations 
occur on the unprimed side of the substrate.  Interestingly also, GlnP2′ and ArgP4′, each 
of which interacts with Asp30, mutate very infrequently.  However, high variability was 
observed at the P1′ and P3′ positions in the p1-p6 substrate, though only either P1′ 
mutates from Leu to the bulkier Phe, or SerP3′ mutates to an Asn, both mutations do not 
occur simultaneously.  Thus the pattern of mutations within the p1-p6 has some 
complexity.  
To further understand the covariation of p1-p6 mutations and the D30N/N88D protease 
mutations, we performed modeling studies from the crystal structure of with the WT 
protease bound to the p1-p6 substrate.  Phe at P1′ fits the S1′ protease pocket much better 
than Leu at P1′ (WT) due to more extensive van der Waals contacts (Fig II.3d and II.3a).  
Similarly, modeling an Asn at the P3′ position may possibly result in interactions with 
Arg8 and Asp29′ not seen with Ser (Fig II.3c and II.3a).  Either mutation may 
compensate for the potentially weaker interactions at P2′ and P4′ with Asp30.  However, 
simultaneously modeling both of the larger mutations at P1′ and P3′ in the S1′/S3′ pocket 
of the protease (Fig II.3e) may lead to steric clashes that could explain why the two 
residues at P1′ and P3′ rarely mutate together. 
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NC-p1 CLEAVAGE SITE 
Mutations at NC-p1 also covaried with the D30N/N88D mutations in the protease 
(χ2=6.83, p=0.009).  In contrast with the p1-p6 site, mutations within the NC-p1 cleavage 
site were negatively correlated to the protease D30N/N88D mutations as indicated by a 
negative phi value (Table II.1).  Of the 21 isolates with the D30N/N88D mutations, only 
14% had mutations in the NC-p1 cleavage site (Table II.1).  Conversely, of the 175 
isolates without the D30N/N88D protease mutations, 47% had NC-p1 mutations, 86 of 
which were AP1V that mostly correlated with the protease mutation V82A.  This 
correlation has been previously observed (Doyon et al., 1996) and explained structurally 
as the NC-p1 cleavage site makes unique interactions with Val82 (Prabu-Jeyabalan et al., 
2004).  The protease mutations V82A and D30N do not occur simultaneously in patient 
sequences (Hoffman et al, 2003; Wu et al., 2003) presumably because the two mutations 
occurring together would adversely impact protease activity.  Since V82A mutates in a 
correlated manner with NC-p1 but not with D30N/N88D, it is consistent that mutations at 
NC-p1 would also be anti-correlated with D30N/N88D. 
CONCLUSION 
Mutations in the HIV-1 protease substrate cleavage-site p1-p6 covary with the 
D30N/N88D protease mutations.  Asp30 is important both to the binding of NFV and 
also likely to the recognition of the p1-p6 cleavage site.  Structural analysis shows that 
both NFV and p1-p6 have atoms that protrude beyond the substrate envelope and contact 
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Asp30.  Thus, both the inhibitor and the p1-p6 substrate are likely to be affected by D30N 
mutation.  This likely explains the particular co-evolution of the p1-p6 cleavage site with 
the D30N resistant mutation and also why no other co-evolution with any of the other 
substrates occurs. 
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CHAPTER III 
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE-
CORRELATED CLEAVAGE SITE MUTATIONS ENHANCE 
INHIBITOR RESISTANCE 
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ABSTRACT 
Drug resistance is an important cause of anti-retroviral therapy failure in HIV-infected 
patients.  Mutations in the protease render the virus resistant to protease inhibitors (PIs).  
Gag cleavage sites also mutate, sometimes correlating with resistance mutations in the 
protease, but their contribution to resistance has not been systematically analyzed.  The 
present study examines mutations in Gag cleavage sites that associate with protease 
mutations and the impact of these associations on drug susceptibilities.  Significant 
associations were observed between mutations in the NC-p1 and p1-p6 cleavage sites and 
various PI resistance-associated mutations in protease.  Several patterns were frequently 
observed, including: mutations in the NC-p1 cleavage site in combination with I50L, 
V82A and I84V within the protease; and mutations within the p1-p6 cleavage site in 
combination with D30N, I50V and I84V within the protease.  For most patterns, viruses 
with mutations both in the protease and in either cleavage site were significantly less 
susceptible to specific PIs than viruses with mutations in the protease alone.  Altered PI 
resistance in HIV-1 was found to be associated with the presence of Gag cleavage site 
mutations.  These studies suggest that associated cleavage site mutations may contribute 
to PI susceptibility in highly specific ways depending on the particular combinations of 
mutations and inhibitors.  Thus, cleavage site mutations should be considered when 
assessing the level of PI resistance. 
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INTRODUCTION 
Combination antiretroviral treatment regimens containing PIs often do not completely 
and durably suppress HIV-1 infection, resulting in therapy failure.  Selective drug 
pressure of competitive PIs has resulted in accumulation of combinations of mutations 
within both Gag and GagProPol polyproteins that render the virus highly resistant to 
multiple drugs (Boden and Markowitz, 1998; Molla et al., 1998; Schinazi, Larder, and 
Mellors, 1997).  In addition, there is an increasing incidence of new infections with 
viruses that are already drug-resistant (Brenner et al., 2002). 
Drug resistance provides an escape mechanism for the virus by lowering the affinity of 
target enzymes for inhibitors while still maintaining efficient processing, thus leading to 
therapy failure (Kantor et al., 2002; Rhee et al., 2003).  This paradox maybe explained 
using the concept of ‘substrate envelope’ which states that substrate specificity is based 
not on a particular amino acid sequence but on a conserved shape (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2002).  The consensus volume of the majority of the substrates 
defines the substrate envelope.  Although most of the volume of any given inhibitor also 
fits within this envelope, particular inhibitor atoms occasionally protrude beyond the 
envelope to contact surrounding protease residues.  Mutations at these residues 
preferentially impact inhibitor binding over substrate recognition and cleavage (King et 
al., 2004a).  Often, these resistance-associated mutations reduce the catalytic efficiency 
of the protease resulting in immature or non-infectious viruses (Croteau et al., 1997).  To 
compensate for this loss in efficiency, secondary mutations develop within the protease 
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(Nijhuis et al., 1999).  In addition, mutations develop within the cleavage sites 
complementing the changes in the resistant protease.  All genotype-based algorithms used 
to predict the susceptibility of patient virus to PIs only assess mutations within the 
protease (Gulnik et al., 1995; Kaplan et al., 1994; Nijhuis et al., 1999).  However, 
resistance-associated mutations in Gag, especially within the cleavage sites, are often 
associated with protease mutations (Bally et al., 2000; Doyon et al., 1996; Feher et al., 
2002; Kolli, Lastere, and Schiffer, 2006; Mammano, Petit, and Clavel, 1998; Zhang et al., 
1997) and may be important for resistance testing.    
Gag A431V, within the nucleocapsid-p1 (NC-p1) cleavage site, was one of the first 
cleavage site mutations to be associated with the V82A protease mutation (Zhang et al., 
1997), and more recently I437V was shown also to be associated with 82 (Nijhuis et al., 
2007).  Association was reported between mutations within the p1-p6 cleavage site and the 
I50V protease mutation (Maguire et al., 2002).  In earlier studies (Kolli, Lastere, and 
Schiffer, 2006) we showed an association between the occurrence of mutations within the 
p1-p6 cleavage site and the signature protease mutations of Nelfinavir (NFV) resistance, 
D30N/N88D (Pai and Nahata, 1999; Patick et al., 1998).  The present study focuses on the 
primary resistance-associated mutations at residues 30, 50, 82, 84, 88 and 90 in the 
protease, and their association with mutations within the Gag cleavage sites, NC-p1 and 
p1-p6 (Fig III.1a-e).   
To further study the impact of these associations, the susceptibility of viruses to various 
PIs was examined by mining a large database of linked genotypes and phenotypic 
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Figure III.1 
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Figure III.1:  Overview of the NC-p1 and p1-p6 Cleavage Sites.  (a) Overview of Gag 
showing the constituent proteins. (b) Details of the p1-p6 cleavage site.  Also shown are 
the two residues, AP2 and LP4′, which mutate frequently. (c) Two different views of the 
crystal structure of HIV-1 protease complexed with NC-p1 cleavage site (King et al., 
2004b) (PDB ID:1TSU).  In green is the substrate and in white and grey are the two 
monomers.  Above is the top view showing van der Waals surfaces on cleavage site 
residues that mutate frequently.  Shown below is the side view with van der Waals 
surfaces on protease residues that are the focus of this study. (d) Details of the NC-p1 
cleavage site.  Residues that mutate frequently are shown. (e) Two different views of the 
crystal structure of HIV-1 protease complexed with p1-p6 cleavage site (King et al., 
2004b) (1KJF).  In green is the substrate and in white and grey are the two monomers.  
Above is the top view showing van der Waals surfaces on cleavage site residues that 
mutate frequently.  Shown below is the side view with van der Waals surfaces on 
protease residues that are the focus of this study.  Images were generated using PyMol 
(DeLano, 2008).
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measures of viral susceptibility to antiretroviral drugs.  Several of these patterns 
significantly alter the virus susceptibility to PIs, indicating that the evolution of drug 
resistance not only occurs within the protease but also involves multiple regions of Gag 
and GagProPol polyproteins in an interdependent manner. 
METHODS 
Sequence Database.  HIV-1 protease (PR, 1-99), reverse transcriptase (RT, 1-305) and 
Gag (Gag, 418-500) sequences were obtained from samples submitted to Monogram 
Biosciences for routine phenotype and genotype drug resistance testing.  Viral sequences 
from infected patients were determined by the GeneSeq™ HIV assay (Petropoulos et al., 
2000).  A data set of 39,152 subtype B sequences from the Monogram Biosciences 
database was used.  Wild type viruses i.e. showing none of the known resistance 
mutations in either protease or reverse transcriptase were excluded.  RT mutations that 
were included are M41L, K65R, D67N, T69, K70ER, L74X, V75A/M/S/T, A98G, 
L100I, K101P, K103N/S, V106A/M, Y115F, Q151M, Y181X, M184X, Y188X, G190X, 
L210W, T215F/Y, K219X, P225X, F227X, M230L, P236L (X stands for any mutation).  
PR mutations that were included are L10X, K20X, L23X, L24X, D30X, V32X, L33X, 
M46X, I47X, G48X, I50X, I54X, A71X, G73X, L76X, V82X, I84X, N88X, L90X.  Only 
one sample per patient was included.  Gag sequence alignments were performed using the 
profile Hidden Markov Model (HMM) software HMMER (http://hmmer.janelia.org).  
The profile HMM was previously constructed from 1,152 gag sequences (data not 
shown).  Amino acid positions were numbered through the alignment with the HXB2 
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consensus sequence.  All statistical analyses were performed using the R software 
environment, version 2.4.1 (http://www.r-project.org). 
Covariation Analysis.  Sequences were analyzed with respect to presence or absence of 
the following primary mutations within the protease, either individually or in 
combination: D30N, I50V, I50L, V82A, I84V, N88D and L90M.  Samples with mixtures 
at particular positions and mutations other than those specified were excluded.  The 
corresponding NC-p1 and p1-p6 cleavage sites were screened for mutations relative to 
HXB2.  The association of cleavage site mutations with a specific protease mutation was 
computed as the proportion of the total number of sequences with that particular protease 
mutation.  These proportions were compared to the case when the cleavage site mutations 
occurred in the absence of any primary protease mutation.  The significance of the 
association was tested by the Chi square test (R function chisq.test).  Adjustments were 
made for multiple testing using the Bonferroni method.  The corrected p-values < 0.05 
indicated statistical significance. 
Replication Capacities (RC).  Relative fitness of the virus was determined with the 
Replication CapacityTM and expressed as a percentage relative to that of a reference virus, 
NL4-3 (Deeks et al., 2001).  RCs for viruses including the protease mutations of interest 
with and without Gag cleavage site mutations were extracted and analyzed.  Difference in 
mean RC was tested using the Mann-Whitney test (R function wilcoxon.test).  
Adjustments were made for multiple testing using the Bonferroni method.  The corrected 
p-values < 0.05 indicated statistical significance. 
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Drug Susceptibilities.  Virus susceptibility to Amprenavir (APV), Atazanavir (ATV), 
Indinavir (IDV), Lopinavir (LPV), Nelfinavir (NFV), Ritonavir (RTV), Saquinavir 
(SQV) and Tipranavir (TPV) was determined with the PhenoSense™ assay (Parkin et al., 
2004; Petropoulos et al., 2000) (Monogram Biosciences, South San Francisco CA).  
Results are expressed as fold change (http://www-fbsc.ncifcrf.gov/HIVdb) in IC50 of the 
patient virus relative to that of the drug-sensitive reference, NL4-3.  FC distribution for 
groups of samples containing certain protease mutations with and without Gag cleavage 
site mutations were extracted and analyzed.  Samples with mixtures at particular 
positions and mutations other than those specified were considered not to meet the profile 
and were excluded.  The difference in median IC50 FC was tested using the Mann-
Whitney test (R function wilcoxon.test).  Adjustments were made for multiple testing 
using the Bonferroni method.  The corrected p-values < 0.05 indicated statistical 
significance. 
Additional Validation Studies.  To help to ensure the validity of our studies the 
following additional studies were performed – 1) the average number of secondary 
protease mutations in viruses with or without particular Gag mutations was computed and 
the difference was evaluated using the t-test.  2) Sequences with and without Gag 
mutations in the absence of protease mutations were extracted from the database.  The 
difference in mean FC in IC50s to various protease inhibitors was evaluated using the t-
test.  3) Two sets of Gag sequences (418-500) were aligned.  The first group consists of 
non-WT samples that were used for the susceptibility analyses and the second group 
consists of sequences that were WT for protease.  The mutation frequency at each Gag 
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position was calculated for both sets and the frequency difference between the two 
groups was plotted. 
RESULTS 
The NC-p1 and p1-p6 cleavage sites (Fig III.1b, d) are essential in the critical final steps 
of viral budding (Sheng et al., 1997) and maturation.  To examine the mutational patterns 
in these two key cleavage sites and their association with HIV-1 protease mutations, data 
was extracted from 39,152 HIV-1, subtype B viral sequences from infected patients.  
These sequences had a median of one PI-associated protease mutations (range 0-8).  
Sequences were examined for associated mutations between D30N, 
D30N/N88D(/L90M), I50V/L, V82A(/L90M), I84V(/L90M) and L90M primary drug-
resistance mutations in protease and mutations within Gag in either the NC-p1 or the p1-
p6 cleavage sites.  Gag A431 within the NC-p1 cleavage site was the most common site 
for associated mutations.  The A431V mutation was observed to associate with the V82A 
protease mutation, as previously reported (Doyon et al., 1996; Zhang et al., 1997).  
Mutations at Gag 431 also associated with either I50L or I84V protease mutations.  
Mutations at Gag 436, another site within NC-p1, associated with the V82A protease 
mutation.  Gag I437V mutation within NC-p1 recently shown to enhance PI resistance 
(Nijhuis et al., 2007) was observed in this study to significantly associate with both V82A 
and I84V protease mutations.  Previously, we observed that mutations at the p1-p6 
cleavage site associate with the D30N/N88D NFV-resistance protease mutations (Kolli, 
Lastere, and Schiffer, 2006).  In the present study p1-p6 mutations were also observed to 
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associate with N88D alone.  In addition, p1-p6 cleavage site mutations associated with 
either I50V or I84V protease mutations, independently.  The particular patterns of 
mutations within the p1-p6 cleavage site varied specifically depending on the particular 
protease mutation.  D30N/N88D and I84V protease mutations associated with mutations 
at Gag L449, S451, R452 and P453 while I50V protease mutation associated with 
mutations at Gag L449, R452 and P453.  Thus, associated mutations were observed in 
either the NC-p1 and/or the p1-p6 cleavage sites in the presence of all the primary active 
site resistance mutations. 
These patterns of associations between cleavage site mutations and particular primary 
protease resistance mutations were further analyzed in terms of RC and drug 
susceptibility.  The effects of additional protease mutations (L10, K20, L23, L24, V32, 
L33, M46, I47, G48, I54, A71, G73 and L76) have not been excluded as attempts to 
exclude them limited the sample size and did not significantly alter the observed 
associations.  However, additional control studies, as detailed below, were performed to 
understand other factors that may likely contribute to alterations in phenotypic 
susceptibility to various inhibitors in addition to the role of Gag mutations.   
Groups of viruses with particular protease mutations in the presence and absence of Gag 
mutations were compared for the number of secondary protease mutations (Supplemental 
Table III.1).  With the exception of viruses with V82A/L90M all viruses with other 
protease mutations in combination with Gag A431V had significantly more secondary 
mutations in the protease.  Of these, only D30N and I50V viruses did not show increased 
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FCs.  Viruses with V82A and V82A/L90M in combination with mutation at Gag 449 had 
slightly more secondary protease mutations and showed higher FCs in IC50 compared to 
viruses without the Gag 449 mutation.  Viruses with mutations at Gag 452 had increased 
number of secondary mutations when in combination with the I84V, I84V/L90M, V82A 
and V82A/L90M protease mutations and also showed a significant in FCs.  A similar 
trend was observed in viruses that had mutations at Gag 453 in combination with V82A 
and V82A/L90M protease mutations. 
Alterations in phenotypic susceptibilities to protease inhibitors as a result of various Gag 
cleavage site mutations in the absence of protease mutations were analyzed (Fig III.2).  
With the exception of IDV and NFV, there were small but statistically significant 
increases in susceptibilities to various protease inhibitors as a result of cleavage site 
mutations alone in the absence of any resistance-associated protease mutations.  
However, both groups of viruses were found to be highly susceptible to all PIs except to 
NFV where a slight reduction in susceptibility was observed. 
Mutation frequencies within Gag were higher in the case of non-WT samples that were 
used in the phenotypic susceptibility analyses as compared to WT sequences (Fig III.3).  
Specifically, Gag 431 and 453, within the NC-p1 and p1-p6 sites respectively, mutated 
much more frequently in non-WT samples as compared to WT sequences.  Increased 
mutational frequencies were also observed at 436, 437, 449 and 452 in the case of the 
non-WT samples as compared to WT samples.  Small increases in mutation frequencies 
were also observed in the PTAP region in the non-WT samples.   
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Figure III.2:  PI susceptibility of viruses with and without Gag mutations in the 
absence of protease resistance mutations.  Mean FCs in IC50 are shown on a log scale 
on the y-axis and the various PIs tested against are shown on the x-axis.  Green bars 
represent viruses with Gag mutations and pink bars represent viruses without Gag 
mutations.  Stars indicate significant differences in susceptibility of the viruses to a 
particular PI.  p-values ≤ 0.05 are significant.
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Figure III.3 
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Figure III.3:  Differential mutation rates within Gag from viruses with and without 
PR resistance mutations.  Mutation frequencies are shown on the y-axis and Gag 
residues numbering 418 to 500 are shown on the x-axis.
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Replication Capacities.  In this study, fitness of groups of viruses with particular 
protease mutations in the presence and absence of Gag mutations were compared to a 
reference virus.  Interestingly, in most instances, viruses with Gag mutations in 
combination with particular protease mutations did not improve fitness as compared to 
that of viruses with mutations in the protease alone (Fig III.4 and Supplemental Table 
III.2).  In fact, in the few cases where significant differences were observed, Gag 
mutations actually decreased fitness as compared to viruses that have protease mutations 
in the absence of Gag mutations.  Both V82A and V82A/L90M viruses had lower RCs in 
combination with mutations at Gag 431 as compared to those without this mutation (Fig 
III.4h and i).  Similarly, mutation at Gag 431 also lowered viral fitness in the presence of 
I84V protease mutation (Fig III.4j).  In addition, viruses with I84V or I84V/L90M 
protease mutations in combination with mutations at Gag 452 also had lower RCs as 
compared to viruses with the protease mutation alone (Fig III.4j and k).  Viruses with 
L90M protease mutation in combination with mutations at either Gag 431, 437 and 453 
were less fit as compared to viruses with L90M alone (Fig III.4l). 
D30N.  D30N is a signature mutation for NFV often in combination with N88D or 
occasionally N88D/L90M (Mitsuya et al., 2006; Patick et al., 1998).  D30N, D30N/N88D 
and N88D protease mutations were not associated (Fig III.5a, b and d) with mutations in 
NC-p1.  However, there was a significant decrease in phenotypic susceptibilities to all 
protease inhibitors in viruses where A431V mutation occurred in combination with 
D30N/N88D(/L90M), N88D or N88D/L90M (Fig III.6a, d and g).  No corresponding 
changes in PI sensitivity were seen with mutations at Gag 436, whereas mutations at Gag 
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Figure III.4 
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Figure III.4 (contd.) 
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Figure III.4:  Replicative Capacities of viruses with primary drug-resistant protease 
mutations and associated NC-p1 and p1-p6 cleavage site mutations.  RCs of viruses 
tested are shown as a percentage of the WT reference virus (100%) on the y-axis and on 
the y-axis are Gag residues within NC-p1 and p1-p6 that mutate frequently.  Closed bars 
represent viruses with both the particular protease and cleavage site mutations present.  
Open bars represent viruses with only the particular protease mutations present.  Stars 
indicate significant difference in RCs for a particular set.  p-values ≤ 0.05 are significant.
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Figure III.5:  Mutations within the NC-p1 and p1-p6 cleavage sites associated with 
primary resistance-associated mutations in the protease at residues 30, 50, 82, 84, 88 
and 90.  The frequency of cleavage site mutations are shown as percentages on the y-
axis.  On the x-axis are the amino acid residues (Gag numbering) within the NC-p1 and 
p1-p6 cleavage sites.  In green are cleavage sites that mutate in the presence of the 
primary protease mutation and in orange are cleavage sites that mutate in the absence of 
the given protease mutations.  Dark green and dark orange indicate significant association 
of mutations.  p-values ≤ 0.05 are significant.
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Figure III.6 (cont.) 
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Figure III.6:  Box plots (ratio of median FCs on a log scale on the Y-axis) showing 
susceptibilities of NFV-resistant viruses to various PIs (on the X-axis) in the presence 
(green boxes) or absence (yellow boxes) of associating mutations within the NC-p1 and 
p1-p6 cleavage sites.  The boxes represent the inter quartile range between the first and 
third quartile.  The upper and lower lines represent 1.5 times the upper and lower quartile 
limits.  The black line represents the median and the red X represents the mean of the 
distribution.  Outliers are shown as open circles.  Dark green and gold boxes indicate 
significant effect of associating mutations within Gag cleavage sites on PI 
susceptibilities.   
(a) Susceptibilities of D30N/N88D viruses with and without mutations at Gag 431.       
(b) Susceptibilities of D30N/N88D viruses with and without mutations at Gag 437.       
(c) Susceptibilities of D30N/N88D viruses with and without mutations at Gag 449.       
(d) Susceptibilities of D30N/N88D/L90M viruses with and without mutations at Gag 431. 
(e) Susceptibilities of N88D viruses with and without mutations at Gag 431.                   
(f) Susceptibilities of N88D viruses with and without mutations at Gag 449.                     
(g) Susceptibilities of N88D/L90M viruses with and without mutations at Gag 431.        
p-values ≤ 0.05 are significant.
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437 in combination with D30N/N88D protease mutations resulted in viruses with reduced 
sensitivity to APV, ATV, IDV, LPV, NFV, RTV and SQV (Fig III.6b).  In contrast, as 
we’ve previously seen, D30N/N88D protease mutations were significantly associated 
with mutations within p1-p6 cleavage site where 32, 30 and 66% of sequences had 
mutations at L449, S451 and P453 respectively whereas only 15, 17 and 30% of 
sequences had mutations at these positions in the absence of D30N/N88D (Fig III.5b and 
Supplemental Table III.3) confirming our earlier studies (Kolli, Lastere, and Schiffer, 
2006).  Although not as frequent, Gag R452 was also observed to mutate in an associated 
manner with D30N/N88D (Fig III.5b).  A similar trend was observed in 
D30N/N88D/L90M viruses (Fig III.5c).  Viruses with D30N/N88D in combination with 
mutations at L449 showed small changes in FC across APV, IDV and SQV (Fig III.6c).  
Mutations within p1-p6 are also associated with the N88D and N88D/L90M protease 
mutations (Fig III.5d and e), and decreased sensitivity to APV, IDV, NFV, SQV and TPV 
was observed in viruses with Gag 449 mutation in combination with N88D (Fig III.6f).  
Thus D30N/N88D and N88D protease mutations associate with mutations within p1-p6, 
in contrast with mutations in NC-p1, although both combinations modulate 
susceptibilities to the PIs.  
I50V and I50L.  I50, positioned at the flap tips of the protease, plays an essential role in 
substrate recognition and cleavage by locking down the active site (Mahalingam et al., 
1999; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002).  This key residue did not mutate 
in response to the first generation PIs, however subsequent PIs result in I50 mutating in a 
drug dependent manner.  The I50L mutation results in severe resistance to ATV, but 
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causes hypersusceptibility to most other PIs (Colonno et al., 2004; Yanchunas et al., 
2005) whereas the I50V mutation results in resistance to APV and to a lesser extent, 
DRV (Delaugerre et al., 2007; Partaledis et al., 1995; Pazhanisamy et al., 1998).  The 
I50L protease mutation was observed to associate with mutations at Gag A431 within the 
NC-p1 cleavage site (Fig III.5f).  Previous studies showed that Gag L449 and P453 
within the p1-p6 cleavage site mutated in an associated manner with the I50V protease 
mutation (Maguire et al., 2002; Maguire et al., 2001) and was also observed here (Fig 
III.5g).  Less frequently, mutations at Gag R452 were also associated with the I50V 
mutation.  In addition, I50V protease mutation was also associated with mutations at 
K436 and I437 within NC-p1 cleavage site (Fig III.5g).  Altered susceptibilities to 
various drugs were observed with both I50L and I50V protease mutations in the presence 
of mutations in NC-p1 and p1-p6 cleavage sites respectively.  Viruses with I50L, a 
signature mutation of ATV resistance, often show hypersusceptibility to other protease 
inhibitors (Sista et al., 2008).  Viruses with I50L in combination with Gag A431V lose 
this hypersusceptibility and show decreased susceptibility to APV, ATV, IDV, LPV, 
NFV and RTV (Fig III.7a).  I50V viruses showed significantly reduced susceptibilities to 
IDV, LPV, NFV and SQV in combination with K436R mutation (Fig III.7b), in 
combination with mutations at Gag 437 showed reduced susceptibility to all PIs (Fig 
III.7c) whereas I50V viruses in combination with Gag L449F showed increased 
susceptibilities to IDV, LPV and especially to RTV (Fig III.7d).  Thus, the impact of 
mutations at I50 is modulated by the addition of particular cleavage site mutations.  
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Figure III.7:  Box plots (ratio of median FCs on a log scale on the Y-axis) showing 
susceptibilities of I50V and I50L viruses to various PIs (on the X-axis) in the presence 
(green boxes) or absence (yellow boxes) of associating mutations within the NC-p1 and 
p1-p6 cleavage sites.  The boxes represent the inter quartile range between the first and 
third quartile.  The upper and lower lines represent 1.5 times the upper and lower quartile 
limits.  The black line represents the median and the red X represents the mean of the 
distribution.  Outliers are shown as open circles.  Dark green and gold boxes indicate 
significant effect of associating mutations within Gag cleavage sites on PI 
susceptibilities.  
(a) Susceptibilities of I50L viruses with and without mutations at Gag 431.  
(b) Susceptibilities of I50V viruses with and without mutations at Gag 436.  
(c) Susceptibilities of I50V viruses with and without mutations at Gag 437.  
(d) Susceptibilities of I50V viruses with and without mutations at Gag 449.   
p-values ≤ 0.05 are significant.
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V82A.  The V82A protease mutation has been well documented to associate with Gag 
A431V (Prabu-Jeyabalan et al., 2006; Zhang et al., 1997).  52% of viruses have this 
combination of mutations whereas only 15% have the A431V mutation in the absence of 
the V82A protease mutation (Fig III.5h and Supplemental Table III.3).  Those viruses 
with both mutations exhibited lower susceptibility to IDV and LPV but were 
hypersusceptible to TPV (Fig III.8a).  However, a significant increase in susceptibility to 
RTV and TPV, to a lesser extent, was observed in viruses with the combination of 
V82A/L90M and Gag A431V mutations (Fig III.8b).  Mutations at Gag 436 and 437 
within the NC-p1 were also associated with both V82A and V82A/L90M protease 
mutations (Fig III.5h and i).  Mutations at Gag K436 were observed to associate with the 
V82A protease mutation, where Gag K436 mutated in 11% and 12% of the viruses in the 
presence while only 5% and 6% mutated in the absence of V82A and V82A/L90M 
respectively (Supplemental Table III.3).  However, no associated changes in 
susceptibilities were observed.  The Gag 437 mutations, which occurred 19% and 20% of 
the time with V82A and V82A/L90M respectively, resulted in reduced sensitivity to all 
PIs (Fig III.8c and d).  Mutations within the p1-p6 site were significantly not associated 
with either V82A or V82A/L90M protease mutations.  Only 10% of viruses had Gag 
L449F mutation and V82A or V82A/L90M protease mutations as opposed to 16% that 
had mutations only in the cleavage site (Fig III.5h, i and Supplemental Table III.3).  
Mutations at Gag L449 in combination with V82A or V82A/L90M decreased 
susceptibilities to all protease inhibitors tested (Fig III.8e and f).  Mutations at Gag P453 
with V82A viruses also showed significantly decreased susceptibilities to all PIs (Fig  
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Figure III.8:  Box plots (ratio of median FCs on a log scale on the Y-axis) showing 
susceptibilities of V82A and V82A/L90M viruses to various PIs (on the X-axis) in the 
presence (green boxes) or absence (yellow boxes) of associating mutations within the 
NC-p1 and p1-p6 cleavage sites.  The boxes represent the inter quartile range between the 
first and third quartile.  The upper and lower lines represent 1.5 times the upper and lower 
quartile limits.  The black line represents the median and the red X represents the mean of 
the distribution.  Outliers are shown as open circles.  Dark green and gold boxes indicate 
significant effect of associating mutations within Gag cleavage sites on PI 
susceptibilities.   
(a) Susceptibilities of V82A viruses with and without mutations at Gag 431.   
(b) Susceptibilities of V82A/L90M viruses with and without mutations at Gag 431.       
(c) Susceptibilities of V82A viruses with and without mutations at Gag 437.  
(d) Susceptibilities of V82A/L90M viruses with and without mutations at Gag 437.       
(e) Susceptibilities of V82A viruses with and without mutations at Gag 449.   
(f) Susceptibilities of V82A/L90M viruses with and without mutations at Gag 449.       
(g) Susceptibilities of V82A viruses with and without mutations at Gag R453.   
(h) Susceptibilities of V82A/L90M viruses with and without mutations at Gag 453.        
p-values ≤ 0.05 are significant.
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III.8g) whereas in combination with V82A/L90M viruses, decreased susceptibilities were 
observed with LPV, RTV and SQV (Fig III.8h).  Thus, with a few exceptions, mutations 
within the NC-p1 and p1-p6 cleavage sites, often modulated by L90M, are seen to 
decrease the susceptibility of V82A protease containing viruses.  
I84V.  Several Gag cleavage site mutations result in viruses with significant decreases in 
susceptibilities when combined with the I84V protease mutation.  Within NC-p1, 
mutation at Gag A431 occurred 53% of the viruses in presence of I84V or I84V/L90M as 
compared to 14% and 16% respectively, in the absence of these protease mutations (Fig 
III.5j, k and Supplemental Table III.3).  Decreased susceptibilities to all protease 
inhibitors were observed when mutations at Gag 431 occurred with either I84V alone or 
I84V/L90M protease mutations (Fig III.9a and b).  Even though no associations were 
observed, mutations at Gag 436 in combination with I84V resulted in decreased 
susceptibility to RTV, whereas in combination with I84V/L90M decreased susceptibility 
to ATV and RTV (Fig III.9c and d).  Mutations at I437 within the NC-p1 were also 
associated with these protease mutations (Fig III.5j and k).  In the case of I84V viruses 
with mutations at Gag 437, a significant reduction to all PIs was observed (Fig III.9e) 
whereas with I84V/L90M viruses, reduced sensitivity was observed to all PIs except 
SQV (Fig III.9f).  Significant association of mutations was also observed between I84V 
and mutations within the p1-p6 cleavage site.  Mutations at Gag L449 and P453 were the 
most common, and mutations at R452 were less frequent.  Gag 449 mutations associated 
with I84V and I84V/L90M, in 35% and 31% of the viruses respectively, as compared to 
13% and 44% respectively, in the absence of I84V and I84V/L90M mutations (Fig III.5j, 
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Figure III.9:  Box plots (ratio of median FCs on a log scale on the Y-axis) showing 
susceptibilities of I84V and I84V/L90M viruses to various PIs (on the X-axis) in the 
presence (green boxes) or absence (yellow boxes) of associating mutations within the 
NC-p1 and p1-p6 cleavage sites.  The boxes represent the inter quartile range between the 
first and third quartile.  The upper and lower lines represent 1.5 times the upper and lower 
quartile limits.  The black line represents the median and the red X represents the mean of 
the distribution.  Outliers are shown as open circles.  Dark green and gold boxes indicate 
significant effect of associating mutations within Gag cleavage sites on PI 
susceptibilities.   
(a) Susceptibilities of I84V viruses with and without mutations at Gag 431.   
(b) Susceptibilities of I84V/L90M viruses with and without mutations at Gag 431.         
(c) Susceptibilities of I84V viruses with and without mutations at Gag 436.   
(d) Susceptibilities of I84V/L90M viruses with and without mutations at Gag 436.         
(e) Susceptibilities of I84V viruses with and without mutations at Gag 437.   
(f) Susceptibilities of I84V/L90M viruses with and without mutations at Gag 437.         
(g) Susceptibilities of I84V viruses with and without mutations at Gag 452.   
(h) Susceptibilities of I84V/L90M with and without mutations at 452.   
(i) Susceptibilities of I84V viruses with and without mutations at Gag 453.   
(j) Susceptibilities of I84V/L90M with and without mutations at Gag 453.   
p-values ≤ 0.05 are significant. 
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k and Supplemental Table III.3).  Mutations at Gag 452 were also associated, to a lesser 
extent, with both I84V and I84V/L90M protease mutations (Fig III.5j and k).  No 
corresponding modulations in drug susceptibilities were observed in either I84V or 
I84V/L90M viruses with mutations at Gag 449.  Significant decreases in susceptibilities 
were observed with APV, ATV, IDV, LPV, NFV and especially RTV and SQV, when 
I84V or I84V/L90M associated with mutations at Gag R452 (Fig III.9g and h).  Viruses 
with mutations at Gag 453 showed reduced susceptibilities to APV, NFV and SQV in 
combination with I84V (Fig III.9i), whereas with I84V/L90M reduced susceptibilities 
were observed with NFV and SQV (Fig III.9j).  Thus, several Gag cleavage site 
mutations, in combination with I84V, modulate the level of susceptibility to various 
protease inhibitors. 
L90M.  L90M protease mutation is most commonly associated with other primary PI-
resistant protease mutations leading to an increase in resistance.  Mutations within both 
NC-p1and p1p6 cleavage sites were not associated when L90M occurred independent of 
other primary protease mutations (Fig III.5l).  Mutations at Gag 431 and 436 decreased 
susceptibilities to all PIs in combination with L90M protease mutation (Fig III.10a and 
b).  Decreased susceptibilities to APV, ATV, NFV and SQV were observed with 
mutations at Gag 449; to ATV and SQV with mutations at Gag 451; to SQV with 
mutations at Gag 452 and to all PIS with mutations at Gag 453 when they occurred in 
combination with the L90M protease mutation (Fig III.10c-f).  Thus, decreased 
sensitivity to various PIs were observed in combination with mutations in both NC-p1 
and p1-p6 cleavage sites.
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Figure III.10:  Box plots (ratio of median FCs on a log scale on the Y-axis) showing 
susceptibilities of L90M viruses to various PIs (on the X-axis) in the presence (green 
boxes) or absence (yellow boxes) of associating mutations within the NC-p1 and p1-p6 
cleavage sites.  The boxes represent the inter quartile range between the first and third 
quartile.  The upper and lower lines represent 1.5 times the upper and lower quartile 
limits.  The black line represents the median and the red X represents the mean of the 
distribution.  Outliers are shown as open circles.  Dark green and gold boxes indicate 
significant effect of associating mutations within Gag cleavage sites on PI 
susceptibilities.                                                                                                                   
(a) Susceptibilities of L90M viruses with and without mutations at Gag 431.                   
(b) Susceptibilities of L90M viruses with and without mutations at Gag 436.    
(c) Susceptibilities of L90M viruses with and without mutations at Gag 449.   
(d) Susceptibilities of L90M viruses with and without mutations at Gag 451.   
(e) Susceptibilities of L90M viruses with and without mutations at Gag 452.   
(f) Susceptibilities L90M viruses with and without mutations at Gag 453.  
p-values ≤ 0.05 are significant. 
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DISCUSSION 
NC-p1 and p1-p6 cleavage sites, two critical sites in Gag processing, were systematically 
analyzed for mutations associated with primary PI resistance mutations in the protease.  
For every single active site protease mutation studied, at least one, often novel, associated 
mutation was observed in either of these two critical cleavage sites.  In this study we 
show that a number of these cleavage site mutations are associated with drug resistant 
mutations within the protease.  While previous studies have shown an increased 
resistance and/or improved fitness for some pairs of protease-cleavage site mutations 
(Bally et al., 2000; Dam et al., 2009; Doyon et al., 1996; Feher et al., 2002; Kolli, 
Lastere, and Schiffer, 2006; Maguire et al., 2002; Mammano, Petit, and Clavel, 1998) our 
analyses reveal that even though only some of these alter fitness, a majority of these 
cleavage site mutations significantly modulate, usually increasing, resistance. 
NC-p1 mutations occurred frequently at Gag 431, 436 and 437, often in combination with 
several highly resistant protease mutations.  Earlier studies have shown that mutations at 
Gag 436 and 437 enhance Gag processing (Dam et al., 2009; Maguire et al., 2002; 
Nijhuis et al., 2007) and increase resistance, although the exact mechanism is not clearly 
understood.  Our study observed that K436R increased resistance to certain PIs in 
combination with I50V, I84V and I84V/L90M mutations in protease and I437V increased 
resistance to all PIs with I50V, V82A and I84V mutations in protease.  Gag 436 and 437 
are further from the catalytic D25 than Gag 431, thus making structural predictions of 
their potential mechanism of action less reliable.  The A431V mutation results in a more 
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efficient cleavage of the NC-p1 cleavage site irrespective of the protease variant (Feher et 
al., 2002) as a result of additional contacts with the protease (Prabu-Jeyabalan et al., 
2004).  A recent study showed that in viruses from heavily treated patients, A431V also 
appeared to directly enhance resistance as a result of this improved NC-p1 processing 
(Dam et al., 2009; Nijhuis et al., 2007).  This non-specific improvement in processing of 
the NC-p1 cleavage site is possibly why this mutation was observed frequently in 
combination with V82A/F, I84V and I50L protease mutations in our study.  Even in 
combination with the D30N protease mutation, that is not associated with A431V, an 
increased level resistance to multiple PIs in the 12% of viruses that have this combination 
was observed.  In the validation studies, unlike with most of the cleavage site mutations, 
generally more secondary mutations were observed in the protease in viruses with A431V 
(Supplemental Table III.1), perhaps contributing to the increased resistance and 
warranting further study.  Overall our study demonstrates that mutations within NC-p1 
result in higher levels of resistance when coupled with specific protease mutations.   
Mutations within the p1-p6 cleavage site occurred frequently in combination with D30N, 
D30N/N88D, I84V and I84V/L90M protease mutations sometimes enhancing resistance 
to various PIs.  However mutations within this cleavage site are negatively associated 
with V82A and V82A/L90M, even while enhancing resistance.  Mutations at Gag 449 
and 453 alone, in the absence of protease mutations, were previously shown not to reduce 
susceptibility to PIs (Maguire et al., 2002), however mutated peptides corresponding to 
these cleavage sites are better substrates for a variety of protease variants (Feher et al., 
2002; Maguire et al., 2002).   L449F may enhance catalytic efficiency as a result of 
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improved van der Waals contacts, as we and others have previously suggested (Feher et 
al., 2002; Kolli, Lastere, and Schiffer, 2006).  The overall improved catalytic efficiency 
from mutations in p1-p6 in combination with specific protease mutations may be part of 
the potential mechanism by which the observed increase in resistance to various PIs 
occurs.   
Other underlying causes for the observed increased levels of resistance were evaluated 
and seem not alter our conclusions.  Systematic analysis of the impact of these associated 
NC-p1 and p1-p6 cleavage site mutations on fitness and susceptibility to PIs showed 
these processes not to be directly coupled.  There were no significant improvements in 
viral fitness due to the cleavage site mutations, even as significant alterations in 
sensitivity to various PIs were observed.  Overall, in resistant viruses, most of the 
changes in this region of Gag (AA 418-500) occurred within the cleavage sites, though 
increased mutation rates were also observed in the PTAP region (Fig III.3) but to a lesser 
extent.  The number of secondary protease mutations observed in viruses with mutation 
in protease with and without Gag cleavage site mutations generally did not show a trend 
(Supplemental Table III.1) except with A431.  Thus the interdependency that leads to 
modulation of resistance appears to be specific between the mutations in protease and the 
mutations in the NC-p1 and p1-p6 cleavage sites.  
This study strongly suggests that association of mutations within Gag cleavage sites and 
the protease contributes to PI susceptibility in an inhibitor specific manner.  Mutations 
within NC-p1 and p1-p6 cleavage sites, in combination with specific protease mutations, 
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were observed to significantly modulate drug susceptibilities.  Frequently, these specific 
combinations enhance PI resistance, while in a few cases increased susceptibility was 
observed.  Modulated sensitivity to PIs due to these mutations may be the result of 
alterations in polyprotein processing and structural adaptations of both the protease and 
Gag proteins (Dam et al., 2009; Ho et al., 2008; Maguire et al., 2002; Nijhuis et al., 1999; 
Nijhuis et al., 2007).  In mutations in either NC-p1 or p1-p6, cases occur that make the 
cleavage site a better substrate, complementing the mutated protease even with protease 
mutations not associated with it and thereby causing increased levels of resistance. 
Further studies are warranted to determine the exact mechanisms and extent to which 
these cleavage site mutations contribute to PI resistance.  The inclusion of Gag during 
genotypic or phenotypic resistance testing may lead to improved accuracy in the 
measurement of viral resistance and have direct implications for evaluating patients 
failing PI therapy.  
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CHAPTER IV 
STRUCTURAL INSIGHTS INTO SUBSTRATE  
CO-EVOLUTION 
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The work presented in the following chapter was a collaborative effort.  Celia Schiffer 
and I conceived and designed the study, Michelle Banfill performed site-directed 
mutagenesis to introduce the D30N and N88D protease mutations, Aysegul Ozen 
expressed and purified the D30N/N88D mutant protease, I set up the crystal trials, solved 
and refined the structures to completion, and I performed the structural analyses with 
inputs from Celia Schiffer.
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ABSTRACT 
HIV-1 protease is one of the main targets for anti-retroviral therapy due to its important 
role in the viral life cycle.  However, the selective pressure of protease inhibitor therapy 
results in a wide spectrum of mutations within the protease that renders the virus resistant 
to protease inhibitors (PIs).  In addition, the virus evolves mutations within the Gag 
cleavage that sometimes correlate with resistance mutations in the protease.  Previously 
we showed that Gag L449F and S451N mutations within p1-p6 cleavage site co-evolved 
with the nelfinavir (NFV)-resistant D30N/N88D protease mutations.  This chapter 
describes X-ray crystallographic studies performed to examine structures of WT and 
NFV-resistant protease in complex with p1-p6 peptide variants.  In the WT protease, 
Asp30 interacts with Arg 452 and Gln 450 within the p1-p6 cleavage site.  With the 
D30N mutation, interactions between 30 and Arg 452 are disrupted as a result of Arg 452 
adopting a new orientation.  This loss of interaction is compensated by the co-evolving 
L449F and S451N mutations in the p1p6 cleavage site.  These mutations significantly 
increase the overall interactions with the protease, both by means of hydrogen bonds and 
van der Waals interactions.  Increased interactions were also observed between Asp 29 
and Ile 50 of the protease and the p1-p6 cleavage peptide.  The structural changes in the 
protease as well as the p1-p6 peptide as a result of the co-evolution suggest an 
interdependency of interactions between the protease and the p1-p6 peptide.  This study 
provides a rationale for co-evolution of cleavage sites within Gag with resistance 
mutations within the protease.
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INTRODUCTION 
Since the identification of HIV-1 protease and the pivotal role it plays in viral maturation, 
the protease has been an important target for anti-HIV drugs.  Protease inhibitors were 
first developed in 1995 and are currently an integral component of highly active 
antiretroviral therapy (HAART).  This combination therapy, which includes both reverse 
transcriptase and protease inhibitors, and more recently, integrase and entry inhibitors, 
has significantly improved prognosis for HIV-1 infected individuals. 
There are nine FDA-approved protease inhibitors (PIs) that are currently being used to 
treat HIV-1 infections.  Despite the tremendous success of PIs in treating HIV infections, 
the evolution of resistance to PIs is a major cause for failure of antiretroviral therapy.  A 
number of mutations develop within and around the active site of the protease, including 
D30N, G48V, I50V/L, V82A/F/T and I84V in response to PI therapy (Shafer and 
Schapiro, 2008).  These mutations result in altered interactions between the protease and 
the inhibitors, leading to decreased binding affinity of the inhibitor to the protease.   
Nelfinavir mesylate (NFV), a peptidomimetic inhibitor, was discovered using structure-
based drug design in 1997 (Kaldor et al., 1997; Kempf et al., 1995; Pai and Nahata, 
1999).  Though initially approved for use in monotherapy, it was later successfully used 
in combination therapy with RT inhibitors (Patick et al., 1996).  Early studies showed 
that the appearance of D30N protease mutation, frequently in association with N88D 
mutation, resulted in severe resistance to NFV (Patick et al., 1998).  Mutations at residues 
35, 36, 46 and 71 within the protease were also observed in combination with the D30N 
  
147 
mutation (Clemente et al., 2003; Johnson et al., 2006; Patick et al., 1998).  In addition to 
the N88D protease mutation, compensatory mutations were also observed in the p1-p6 
cleavage site in combination with the NFV-resistant D30N mutation (Kolli, Lastere, and 
Schiffer, 2006; Kolli et al., 2009). 
The D30N protease mutation is selected specifically in response to NFV both in viral 
cultures and in patients being treated with NFV (Patick et al., 1998).  Structural studies 
have revealed that Asp 30 interacts with NFV through a sidechain-mediated hydrogen 
bond that contributes to inhibitor affinity (Kaldor et al., 1997).  However, recent studies 
on protease variants carrying the D30N mutation have shown that this hydrogen bond is 
still maintained (Clemente et al., 2003; Kozisek et al., 2007).  The loss of affinity for 
NFV has been attributed to a large decrease in conformational entropy on binding of the 
inhibitor, loss in hydrogen bonding strength and acid-base interactions (Clemente et al., 
2003; Kozisek et al., 2007).    
Asp 30 is not only important for inhibitor binding but is also essential for recognition of 
the p1-p6 cleavage site (Kolli, Lastere, and Schiffer, 2006; Prabu-Jeyabalan, Nalivaika, 
and Schiffer, 2002b).  Alteration in affinity for NFV as a result of the D30N mutation 
(Kozisek et al., 2007) is also likely to compromise p1-p6 recognition and binding leading 
to its co-evolution (Chapter II).  Mutations within p1-p6 cleavage site co-evolve with the 
D30N/N88D protease mutations associated with NFV resistance (Chapter II and III). 
Specifically, Gag 449, 451 and 453 within the p1-p6 cleavage site were observed to 
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mutate frequently.  Mutations in p1-p6 cleavage site decrease susceptibility of the virus to 
NFV when present in combination with D30N88D protease mutations (Chapter III). 
Within the p1-p6 cleavage site, mutations were observed at either Gag 449 or 451 but not 
simultaneously, in combination with D30N/N88D protease mutations (chapter II); (Kolli, 
Lastere, and Schiffer, 2006).  Gag 449 mutated frequently from Leu to Phe, whereas Ser 
at Gag 451 mutated frequently to an Asn.  In both cases, the mutations resulted in a larger 
amino acid interacting with the surrounding protease residues.  Modeling studies 
described in Chapter II suggested that the mutation to a larger Phe or Asn likely improves 
van der Waals interactions with the surrounding protease residues, thus compensating for 
the loss of interactions with Asp 30.  However, the simultaneous occurrence of both 
mutations is infrequent, suggesting the likelihood of van der Waals clashes leading to 
inefficient processing of the p1-p6 cleavage site.  Several studies have shown that Phe at 
Gag 449 in p1-p6 makes it a better substrate for the wild type (WT) protease, thus 
enhancing processing at this site (Feher et al., 2002; Maguire et al., 2002).  The observed 
interdependency of molecular interactions likely plays a role in the co-evolution of the 
p1-p6 cleavage site. 
This chapter focuses on elucidating the structural rationale for the co-evolution of p1-p6 
cleavage site with the NFV-resistant D30N/N88D HIV-1 protease.  Crystal structures of 
WT and D30N/N88D HIV-1 proteases in complex with WT and mutant p1-p6 substrate 
variants were determined.  Structural changes in the protease as well as the p1-p6 peptide 
  
149 
as a result of the mutations indicate an interdependency of interactions between the 
protease and the p1-p6 peptide.  
MATERIALS AND METHODS 
Nomenclature.  HIV-1 protease variants (WT or D30N/N88D) and the p1-p6 substrate 
variants will be distinguished as subscripts throughout this chapter.  For example, WT 
protease in complex with WT p1-p6 is denoted by PRWT – p1-p6WT and mutant protease 
in complex with S451 mutation in p1-p6 is denoted by PRD30N/N88D – p1-p6S451N.   
Substrate Peptides.  Decameric peptides corresponding to the p1-p6 processing site 
within the Gag polyprotein (AA 444-453) and its variants were purchased from Quality 
Controlled Biochemicals, Inc., Hopkinton, MA.  The following peptide variants were 
used in the x-ray crystallographic structural studies described in the subsequent sections:  
(1) p1-p6WT – RPGNFLQSRP (2) p1-p6L449F – RPGNFFQNRP (3) p1-p6S451N – 
RPGNFLQNRP and (Collaborative-Computational-Project) p1-p6L449F/S451N – 
RPGNFFQNRP. 
D30N/N88D Protease Gene Construction.  The clade B wild-type (WT) protease gene 
was constructed synthetically using codons optimized for protein expression in 
Escherichia coli as previously described with the Q7K mutation introduced to prevent 
autoproteolysis (Rose, Salto, and Craik, 1993).  The D25N was introduced to inactivate 
the protease and prevent substrate cleavage.  The D30N/N88D protease mutations were 
then introduced sequentially into the gene.  Mutations were introduced using the Quik-
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Change™ site-directed mutagenesis kit (Stratagene ®, La Jolla, CA) and confirmed by 
sequencing.  
Protein Expression and Purification.  Expression and purification of the inactive WT 
and D30N/N88D protease variants was performed as previously described (Prabu-
Jeyabalan et al., 2004).  Briefly, the protease gene was sub-cloned into the heat-inducible 
pXC35 expression vector (American Type Culture Collection (ATCC), Manassas, VA) 
and transformed into E. coli TAP-106 cells.  Transformed cells were grown at 30°C till 
A600= 0.6 and induced by raising the temperature to 42°C.  Cells were allowed to grow 
for 4 hours and lysed to release the protease-containing inclusion bodies.  The protease 
was extracted with 50% acetic acid and purified by gel filtration on a 2.1L Sephadex G-
75 superfine (Sigma Chemicals) column equilibrated with 50% acetic acid.  The purified 
protease was refolded by rapid 10-fold dilution into a buffering solution (refolding 
buffer) containing 0.05 M sodium acetate (pH 5.5), 10% glycerol, 5% ethylene glycol, 
and 5mM dithiothreitol.  The refolded protein was concentrated and dialyzed to remove 
any residual acetic acid.  The protease was further purified with a Pharmacia Superdex 75 
fast performance liquid chromatography (FPLC) column equilibrated with refolding 
buffer. 
Crystallization and Data Collection.  Crystals used in this study were obtained under 
multiple conditions.  Protease solutions between 1.0 and 2.2 mg mL-1 were equilibrated 
with a ten-fold molar excess of the p1-p6 peptide variants, individually, for 1 hour on ice.  
Crystals used were grown by the hanging drop vapor diffusion method over a reservoir 
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solution consisting of one of the following three buffer solutions – 1) 126-mM sodium 
phosphate buffer (pH 6.2), 63-mM sodium citrate, and 20% to 32% ammonium sulfate 2) 
0.1-0.5M MES monohydrate buffer (pH 6.5), 0.1-0.4M ammonium sulphate, and 20-31% 
PEG MME 5000 3) 0.1M citrate (pH 5.5), 0.5-3.0M ammonium sulphate.  X-ray 
diffraction data for PRD30N/N88D —p1-p6S451N was collected on the BioCARS beamline 
14-BMC at the Advanced Photon Source (Argonne National Laboratory, Argonne, IL) at 
a wavelength of 0.9 Å with a Quantum 315 CCD X-ray detector (Area Detector Systems 
Corporation, Poway, CA).  Diffraction data for the other 5 complexes were collected on 
the BioCARS beamline 14-IDB at a wavelength of 1.033 Å with a Mar 165 CCD X-ray 
detector (Rayonix, LLC, Evanston, Illinois).  All data were collected under cryo-cooled 
conditions. 
Structure Solution and Crystallographic Refinement.  The data were indexed and 
scaled using HKL-2000 software (HKL Research, Charlottesville, VA).  Structures were 
solved and refined using the CCP4 program suite (Collaborative-Computational-Project, 
1994).  The Matthews co-efficient was calculated for all structures to determine the 
number of molecules in the asymmetric unit.  For complexes with two molecules in the 
asymmetric unit, structure solution was carried out using the molecular replacement 
package Phaser (McCoy et al., 2007), whereas for complexes with one molecule in the 
asymmetric unit, AMoRe was used (Navaza, 1994).  The structure of darunavir 
(inhibitor) in complex with active protease was used as the starting model (1T3R; 
(Surleraux et al., 2005).   ARP/wARP was used to build solvent molecules into the 
electron density (Langer et al., 2008).  Refinement was carried out using a combination 
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of TLS (Winn, Isupov, and Murshudov, 2001) and restrained refinement using Refmac5 
(Murshudov, Vagin, and Dodson, 1997).  Each cycle of refinement was followed by 
model building and real space refinement performed using COOT, a molecular-graphics 
software (Emsley and Cowtan, 2004).  For all complexes, the peptides were built into the 
Fo-Fc electron density after two rounds of refinement cycles.  The working R (RWork ) and 
its cross validation (RFree ) were monitored throughout refinement.  The quality of the 
structures was assessed using MolProbity (Davis et al., 2007). 
Structure Analyses.  Comparisons of the crystal structures were made by superposing 
Cα atoms of the terminal regions (residues 1 to 9 and 86 to 99) from both monomers onto 
a previously solved structure of WT protease in complex with WT p1-p6 (PRWT—p1-
p6WT) (PDB 1KJF; (Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002b).  Structures were 
visualized using PyMol molecular-graphics software (DeLano, 2002). 
For structures with two molecules in the asymmetric unit, RMSDs were calculated and 
double-difference plots generated to visualize structural differences, if any, between the 
two molecules as previously described (Prabu-Jeyabalan et al., 2006).  Briefly, distances 
between all the Cα atoms within the dimer were calculated for each complex.  A 
distance-difference matrix was then computed for each atom for a given pair of 
complexes.  The distance-difference matrix was then plotted as a contour plot using 
GNUPLOT plotting software.   
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Hydrogen Bonds and van der Waals Contacts 
Hydrogen bond interactions were determined using the default settings of the HBPLUS 
program (McDonald, 1994).  van der Waals interaction energies between protease and the 
p1-p6 peptide were computed using a simplified Lennard-Jones potential, V(r) using the 
relation 4ε[(σ/r)12 – (σ/r)6], where r is the protease-p1-p6 interatomic distance and ε and σ 
are the depth of the potential well and collision diameter, respectively for each protease 
substrate atom pair.  V(r) is computed for all possible protease-p1-p6 atom pairs within 
5.0 Å and potentials for nonbonded pairs separated less than a distance at the minimum of 
the potential were equated to - ε.  Using this simplified potential for each non-bonded 
protease-p1-p6 atom pair, total van der Waals contact energy, ΣV(r) was then computed 
for each protease and p1-p6 residue. 
RESULTS 
Overall Structure of the Complexes 
The four decameric p1-p6 substrate variants were crystallized in complex with inactive 
variants of WT and NFV-resistant D30N/N88D HIV-1 protease.  Crystals were 
successfully grown and data obtained for all complexes.  Structures were solved for all 
complexes, except PRD30N/N88D – p1-p6L449F, to a resolution between 1.6 – 1.9 Å (Table 
IV.1).  Four complexes were solved in the P21 space group with two molecules in the 
asymmetric unit, and two were solved in the P212121 with one molecule in the 
asymmetric unit.  In the structures where there are two molecules in the asymmetric unit, 
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Table IV.1 
Variable PRWT PRD30N/N88D PRWT PRWT PRD30N/N88D PRWT PRD30N/N88D 
 - p1-p6WT - p1-p6WT - p1-p6L449F - p1-
 
- p1-
 
- p1-p6 
 
- p1-
         
Data collection        
Space group P212121 P21 P21 P212121 P21 P212121 P21 
a (Å) 51.29 51.67 51.14 51.19 51.55 50.94 51.47 
b (Å) 59.07 60.11 62.79 58.3 60.07 58.41 59.54 
c (Å) 61.81 60.2 61.46 61.36 60.23 61.46 59.36 
β-angle 90 99.09 98.03 90 99.25 90 98.6 
Z 4 8 8 4 8 4 8 
Temperature (°C) -80 -80 -80 -80 -80  -80 
Resolution (Å) 2.0 1.78 1.85 1.75 1.68 1.65 1.9 
Total Reflections 41786 133292 113050 109140 167489 155872 126355 
Unique Reflections 12376 34288 28931 14456 41265 22296 32879 
R merge (%) 6.7 6.8 7.3 4.5 6.6 8.7 6.4 
Completeness (%) 93.4 99.2 99.7 96 99.8 98.1 98.8 
        
Crystallographic 
 
       
R value (%) 20.3 20.04 16.30 14.13 17.97 17.30 20.01 
R free (%) 25.1 25.46 21.28 17.48 22.89 20.45 24.44 
RMSD in:        
Bond length (Å) 0.006 0.009 0.009 0.009 0.009 0.009 0.009 
Bond angles 1.3 1.404 1.423 1.461 1.460 1.457 1.441 
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Table IV.1:  Crystallographic Statistics for WT and D30N/N88D Protease Complexes with the Four p1-p6 Peptide 
Variants.  The statistics for the PRWT—p1-p6WT structure are also included for reference.
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the p1-p6 peptide could be modelled unambigously in at least one of the complexes.  
Additionally, because previously solved structures of substrate complexes from earlier 
studies have shown that Gag 444 and 453 have little contact with the protease and are 
often disordered, differences between the molecules observed at Gag 444 and 453 of the 
peptide were not taken into account.  The structural differences between the two 
molecules are not significant as observed by the the double difference plots (Fig IV.1 a-d) 
and RMSDs which range between 0.14-0.19 (for the entire protease) and 0.11-0.16 for 
the p1-p6 peptide.  Therefore, in the subsequent structural analyses, only one molecule 
from the asymmetric units was chosen based on the unambiguous location of sidechains 
for residues Gag 447-452 within the density.  The complete crystallographic statistics are 
listed in Table IV.1.   
All structures are similar to the previously solved PRWT—p1-p6WT structure, with 
RMSDs ranging from 0.36 to 0.64.  The three WT protease complexes show backbone 
shifts in the flap-hinge region compared to the PRWT—p1-p6WT structure (RMSDs 0.36-
0.4) (Fig IV.2a).  Backbone shifts are also observed at residues 11-22, which form part of 
the protease core.  This region is surface exposed and is known to be flexible.  Structures 
of the three D30N/N88D protease complexes are also very similar to each other (RMSDs 
0.13-0.3) (Fig IV.2b).  However, they all differ from the PRWT—p1-p6WT in the flap-
hinge region and the β-strand 6 (AA 69-78) especially in monomer a, with shifts upto 1.5 
Å.  The differences in the flap-hinge region are likely due to the effect of crystal packing.  
The change in β-strand 6 is likely due to the N88D protease mutation and will be 
described in the following sections.
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 Figure IV.1 
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Figure IV.1:  Double difference plots comparing the two molecules in the asymmetric unit.  (a) PRD30N/N88D—p1-p6WT (b) 
PRWT—p1-p6L449F (c) PRD30N/N88D —p1-p6S451N and (d) PRD30N/N88D —p1-p6L449F/S451N .  The color contours indicate distance 
differences of < 1.0 Å (black), -1.0 to -0.5 Å (green), 0.5 to 1.0 Å (Vivés, Brodin, and Leblue) and > 1.0 Å (red). 
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Figure IV.2 
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Figure IV.2: Cartoon Diagram for Superposition of the Protease-p1-p6 Complexes. (a) Superposition of WT proteases in 
complex with the p1-p6 peptide variants.  (b)  Superposition of D30N/N88D proteases in complex with the p1-p6 eptide 
variants. (c)  Superpositions of all the p1-p6 peptides.
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For all structures used in the analyses, including the previously solved PRWT—p1-p6WT, 
nine substrate residues from Gag 447 to 453 are unambiguously located within the 
electron density map.  All the p1-p6 substrate peptides bound to the protease in the same 
extended conformation as shown in previous studies (Prabu-Jeyabalan, Nalivaika, and 
Schiffer, 2000; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002b), and the side chains of 
residues Gag 447 through 451 are similarly oriented (Fig IV.2c).  However, they all differ 
significantly from the PRWT—p1-p6WT structure in that the sidechain for Arg 452 is 
oriented in a different direction.  The details of the resulting structural alterations are 
discussed in the following sections. 
Hydrogen Bonds 
All the p1-p6 complexes with WT and D30N/N88D protease variants show an extensive 
network of conserved hydrogen bonds, similar to previously solved substrate complexes 
(Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002b).  The five water molecules that bridge 
the peptide to the protease are also conserved across all six structures (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2002b).  In all the complexes, including the PRWT—p1-p6WT, 
30a does not make any sidechain-mediated hydrogen bonds with the p1-p6 peptide.  
Though residue 88 is not in direct contact with either p1-p6 or 30, alterations in the 
hydrogen bonding network around this residue are observed.  Significant differences in 
hydrogen bonds observed around protease residues 30b  and 88 are described below. 
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Hydrogen bonds around 30b.  The most significant changes in hydrogen bonds are 
observed due to the D30N protease mutation (Fig IV.3a-g).  The Gln 450 NE1 to Asp 30b 
OD1 hydrogen bond is conserved across all structures.  Asp 30b also forms a hydrogen 
bond with a water molecule that is conserved across the WT complexes with all the p1-p6 
substrate variants. In the case of PRWT—p1-p6WT, strong electrostatic interactions are 
observed between NE and NH1 of Arg 452 and OE2 of Asp 30b (Fig IV.3a).  In all the 
other complexes Arg 452 is flipped away from residue 30b and these electrostatic 
interactions are lost (Fig IV.3b-g).  In all complexes except the PRWT—p1-p6WT 
structure, Arg 452 makes at least one hydrogen bond with water or other solvent 
molecules including glycerol and ethylene glycol.  Additionally, Arg 452 NE makes a 
water mediated hydrogen bond with 30b OD1/2 in all except the PRWT—p1-p6WT 
structure.  In PRD30N/N88D —p1-p6S451N and PRWT—p1-p6S451N complexes the Asn 451 
forms hydrogen bonds with Arg 8a (Fig IV.3d and e) as well as water molecules, thus 
resulting in increased interactions as compared to Ser 451 in the PRWT—p1-p6WT and 
PRWT—p1-p6L449F and PRD30N/N88D—p1-p6WT structure (Fig IV.3a-c).  Thus the loss of 
hydrogen bond interactions with 30b as a result of the flipped Arg 452 appears to be 
compensated by several other hydrogen bonds.  
Hydrogen bonds around 88.  There is a network of hydrogen bonds that extend from 88 
that help orient this residue in this region, both in monomer a and b of the protease (Fig 
IV.4 a-g) .  In all the WT complexes with the p1-p6 variants, Asn 88 ND1 forms a 
hydrogen bond with Thr74 O.  As a result of the N88D mutation, residue 88 is unable to 
maintain this hydrogen bond with Thr74.  Instead, 88 flips slightly inwards and the OE1
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Figure IV.3 
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Figure IV.3 (cont.) 
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Figure IV.3:  Hydrogen Bond Interactions of the p1-p6 Peptide. (a) PRWT—p1-p6WT (b) PRD30N/N88D—p1-p6WT (c) PRWT—
p1-p6L449F, (d) PRWT—p1-p6S451N, (e) PRD30N/N88D—p1-p6S451N, (f) PRWT—p1-p6L449F/S451N, (g) PRD30N/N88D—p1-p6L449F/S451N.  
The orientation of Arg 452 and the hydrogen bonds around 30b in all structures are shown. Hydrogen bonds around Gag 451 
are also significantly altered. 
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Figure IV.4 
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Figure IV.4 (cont.) 
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Figure IV.4:  Hydrogen Bond Network Around Residue 88.  (a) PRWT—p1-p6WT (b) PRD30N/N88D—p1-p6WT (c) PRWT—p1-
p6L449F, (d) PRWT—p1-p6S451N, (e) PRD30N/N88D—p1-p6S451N, (f) PRWT—p1-p6L449F/S451N, (g) PRD30N/N88D—p1-p6L449F/S451N.  
Loss of interactions with Thr 74 as a result of the N88D mutation are shown.  Asp 88 shows significant deviation from the WT 
Asn.
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makes a hydrogen bond with Thr31 N.  Additionally, N88D O forms a hydrogen bond 
with Thr91 OG1  and N88D OE2 hydrogen bonds with Leu89 N, further stabilizing this 
residue.  The hydrogen bond between 88 OE1 and Thr31 OG1 are conserved across all 
complexes, including the previously solved PRWT—p1-p6WT structure.   
Van der Waals Interactions 
Significant but similar changes in the overall van der Waals interactions are observed in 
all the structures compared to the PRWT—p1-p6WT structure as revealed by the interaction 
energies.  Analysis of the van der Waals interaction energies of the active site residues 
show significant interactions between active site residues of monomer b and the p1-p6 
peptide, and large but similar changes in interaction energies are observed in all 
structures compared to the PRWT—p1-p6WT (Fig IV.5).  In contrast, the few contacts 
between monomer a and the p1-p6 peptide remain relatively constant across all seven 
structures (Fig IV.5).  A more detailed examination reveals reduced interactions between 
30b and the p1-p6 peptide for all structures compared to the PRWT—p1-p6WT structure 
(Fig IV.5).  In contrast, for all structures except PRWT—p1-p6WT, the van der Waals 
interaction energies of D29b increase significantly and in a similar manner, indicating 
increased interactions with the p1-p6 peptide (Fig IV.5).  A similar increase in favorable 
van der Waals interactions are also observed between residues 47 48 and 50 of monomer 
b and the p1-p6 peptide of all structures compared to PRWT—p1-p6WT, but to a smaller 
extent (Fig IV.5). 
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a) 
c) 
b) 
Figure IV.5 
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g) 
f) 
e) 
d) 
Figure IV.5 (cont.) 
  
172 
 
Figure IV.5:  The Total van der Waals Interaction Energies for Active Site Residues 
in Protease.  The interaction energies for residues in monomer a are shown in blue and 
those for residues in monomer b are shown in magenta. (a) PRWT—p1-p6WT (b) 
PRD30N/N88D—p1-p6WT (c) PRWT—p1-p6L449F, (d) PRWT—p1-p6S451N, (e) PRD30N/N88D—
p1-p6S451N, (f) PRWT—p1-p6L449F/S451N, (g) PRD30N/N88D—p1-p6L449F/S451N.  No significant 
changes in interaction energies are seen in monomer a.  In the case of monomer b, 
mutations in protease or p1-p6 result in decrease van der Waals interaction energy at 30, 
which are compensated by interactions made by 29b.
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Analysis of the van der Waals interaction energies of the p1-p6 peptide with the protease 
shows that the overall contacts made by each residue of the peptide follows a common 
trend across all structures (Fig IV.6 a-g).  However, the most significant change is 
observed in the PRWT—p1-p6L449F (Fig IV.6c), PRWT—p1-p6L449F/S451N (Fig IV.6d) and 
PRD30N/N88D—p1-p6L449F/S451N (Fig IV.6g) structures as a result of the larger Phe at Gag 
449, leading to increased interactions with the surrounding protease residues, as 
compared to the PRWT—p1-p6WT structure (Fig IV.6a).  A similar increase in favorable 
interactions is observed in PRWT—p1-p6S451N (Fig IV.6d), PRD30N/N88D—p1-p6WT (Fig 
IV.6b) and PRD30N/N88D—p1-p6S451 (Fig IV.6e), though not to the same extent. At least in 
the case of the PRWT—p1-p6S451N (Fig IV.6d and Fig IV.7d) and PRD30N/N88D—p1-p6S451 
(Fig IV.6e and Fig IV.7e) structures this could be due to the larger Asn in the same 
pocket of the protease resulting in more favorable contacts with Leu 449.  To investigate 
this, the van der Waals interactions made by the p1-p6 peptide from residues 449 to 452 
were examined in detail.  Lastly, van der Waals interactions between 30b and the peptide 
were also examined. 
Interactions at Gag 449.  Parallel to the increased overall van der Waals energies at Gag 
449 observed in the previous section, a detailed examination of interactions reveals  that 
more favorable and more number of interactions are made with the protease in the 
PRWT—p1-p6L449F and PRD30N/N88D —p1-p6 L449F/S451N structures (Table IV.2).  However, 
a similar increase is not observed in the PRWT—p1-p6 L449F/S451N and the interactions are 
comparable to those seen in the PRD30N/N88D —p1-p6S451N, PRD30N/N88D—p1-p6WT, and 
PRWT—p1-p6S451N structures as indicated by the van der Waals interaction energies. 
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Figure IV.6 
b) 
c) 
d) e) 
f) g) 
a) 
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Figure IV.6:  Total van der Waals Interaction energies of the p1-p6 Peptide. (a) 
PRWT—p1-p6WT (b) PRD30N/N88D—p1-p6WT (c) PRWT—p1-p6L449F, (d) PRWT—p1-p6S451N, 
(e) PRD30N/N88D—p1-p6S451N, (f) PRWT—p1-p6L449F/S451N, (g) PRD30N/N88D—p1-
p6L449F/S451N.  No significant differences are observed in the overall trend in van der 
Waals interaction energies across all the structures.  Increased van der Waals energies are 
observed at Gag 449 and 451 in all structures as compared to the PRWT—p1-p6WT 
structure.
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Figure IV.7 
  
177 
Figure IV.7 (cont.)  
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Figure IV.7:  van der Waals Interactions around p1-p6 Peptide Residues Gag 449 and Gag 451. (a) PRWT—p1-p6WT (b) 
PRD30N/N88D—p1-p6WT (c) PRWT—p1-p6L449F, (d) PRWT—p1-p6S451N, (e) PRD30N/N88D—p1-p6S451N, (f) PRWT—p1-p6L449F/S451N, 
(g) PRD30N/N88D—p1-p6L449F/S451N.  Increased van der Wals interactions are observed at Gag 449 and Gag 451 upon mutation.
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Table IV.2:  Side Chain van der Waals Interaction Energies for Gag 449-452 of p1-
p6 Peptide and 30b of Protease.  These van der Waals interaction energies were 
calculated for only the side chains.
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Thus, there is increased van der Waals interactions with the protease as result of the 
mutation from Leu to a larger Phe. 
Interactions at Gag 450.  Overall, Gln 450 makes the most number of favorable contacts 
with the protease as indicated by the large van der Waals interaction energies (Fig IV.6a-
g).  These are comparable to the PRWT—p1-p6WT and did not vary significantly 
irrespective of the protease or the p1-p6 variant.  The energies of the specific interactions 
with the protease also follow the same trend (Table IV.2).  
Interactions at Gag 451.  Interactions made by Gag 451 with the protease are observed 
in the PRWT—p1-p6S451N (Fig IV.6d and Fig IV.7d), PRD30N/N88D —p1-p6S451N (Fig IV.6e 
and Fig IV.7e), PRWT—p1-p6L449F/S451N (Fig IV.6g and Fig IV.7f) and PRD30N/N88D—p1-
p6L449F/S451N (Fig IV.6g and Fig IV.7g) complexes with the Ser to Asn mutation within 
the p1-p6, and were the most favorable as indicated by the overall van der Waals 
interaction energies.  Analysis of the the specific interactions reveals a large increase in 
favorable contacts with Arg 8a as a result of the S451N mutation in the p1-p6 peptide in 
these complexes.  The S451N mutation also leads to increased contacts with residues 29b 
and 48b of the protease.  Thus, Gag 451 makes more favorable van der Waals 
interactions with the protease as a result of the S451N mutation. 
Interactions at Gag 452.  The overall van der Waals energies show very little 
differences in the total interactions between Arg 452 and the protease (Fig IV.6).  
However, a detailed examination of the individual interactions reveals that though the 
Arg 452 in the  PRWT—p1-p6WT interacts with more protease residues as compared to all 
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the other structures, the sum total energies of the interactions are much less favorable 
(Table IV.2).  Although Arg 452 is oriented a different direction in all the structures 
compared to the PRWT—p1-p6WT structure, the change in interactions with protease 30b 
is not notable as indicated by the energies.  Most significant are the interactions with 
protease 8a and 29b, which are not seen in the PRWT—p1-p6WT structure.  
Packing around 30b.  The D30N mutation does not involve changes in the size of the 
side chain.  However, significant decreases in the total van der Waals interactions 
between 30b and the p1-p6 peptide are observed in all structures when  compared with 
the PRWT—p1-p6WT structure (Fig IV.5).  The  specific interactions between 30b and Gag 
450 are similar across all structures except PRWT—p1-p6S451N (Table IV.2).  Interactions 
with Gag 451 are very similar for all the structures.  30b makes more interactions with 
Gag 452 PRWT—p1-p6S451N and PRWT—p1-p6L449F/S451N compared to the remaining 
complexes (Table IV.2).  Though the interactions made by 30b with Gag 450, 451 and 
452 residues of the p1-p6 peptide vary slightly between structures, the overall van der 
Waals interactions are very similar across all structures as indicated by the interaction 
energies (Table IV.2).  
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DISCUSSION 
Cleavage sites within Gag co-evolve with primary PI-resistance mutations in the HIV-1 
protease (Bally et al., 2000; Doyon et al., 1996; Mammano, Petit, and Clavel, 1998; 
Zhang et al., 1997).  Previous studies have shown that the p1-p6 cleavage site co-evolves 
with the D30N/N88D protease mutations that arise specifically in response to NFV 
therapy (Chapter II and III).  This study reports novel data on structural changes in 
protease and p1-p6 cleavage site as a result of p1-p6 coevolution with the D30N/N88D 
protease mutations. 
As shown in Chapter II, p1-p6 cleavage site mutations at Gag 449 and 451 mutate in a 
correlated manner with the NFV-resistant D30N/N88D protease mutations.  Specifically, 
Leu at Gag 449 mutates frequently to Phe and Ser at Gag 451 mutates to an Asn.  In order 
to study the structural changes as a result of these mutations, x-ray crystallographic 
studies were performed with the WT and D30N/N88D protease variants in complex with 
the different p1-p6 substrate variants.  Crystals and diffraction data were obtained for all 
seven complexes after considerable effort, however, the structure of the PRWT—p1-
p6L449F  could not be solved.  Though several crystallization conditions were used, this 
complex crystallized in only one set of buffer conditions and were fragile and plate-like, 
probably resulting in the poor diffraction data. 
Overall, the structures of both WT and D30N/N88D protease complexed with the 
different p1-p6 peptides were very similiar to the structure of WT protease complexed 
with WT (Fig IV.2a,b).  Though some backbone shifts were observed in the flap-hinge 
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region and the surface-exposed region of the core of the protease, these differences are 
likely due to changes in the crystal packing and flexibility of the solvent exposed part of 
the core region.  The most striking difference is observed in the orientation of the Arg at 
Gag 452.  In all the structures where, either the protease or the substrate is mutated, Arg 
452 is oriented differently when compared to the PRWT—p1-p6WT structure (Fig IV.2c). 
This difference, could not be attributed to differences in crystal packing or buffer 
conditions, as there are no crystal contacts or symmetry related contacts in that region, 
nor were there any consistent differences in buffer conditions.  In the PRWT-p1-p6WT 
structure, Arg 452 is part of a hydrogen bonding network involving Asp 30b and Gln 
450.  The altered conformation of Arg 452 in all the other structures leads to the loss of 
its hydrogen bond with Asp 30b. 
Previous studies have shown that Asp 30b of the protease is important for recognition of 
the p1-p6 cleavage site (Kolli, Lastere, and Schiffer, 2006; Prabu-Jeyabalan, Nalivaika, 
and Schiffer, 2002a).  In Chapter II, the modeling studies suggested that the D30N 
mutation would disrupt the network of hydrogen bonds between Gln 450, Asp 30b and 
Arg 452.  Structural studies in this chapter revealed that the D30N mutation serves to 
disrupt the hydrogen bonds with Arg 452 only (IV.3a-g).  A similar disruption of 
hydrogen bond network was also observed in structures of the WT protease complexes 
with the various p1-p6 peptides due to the different orientation of Arg 452.  However, a 
water mediated hydrogen bond between Asp/Asn 30b OD1/ND2 and Arg8a NE 
compensates for the loss of the hydrogen bond between Asp 30b and Arg 452. 
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Additionally, Arg 452 forms several new hydrogen bonds with water or other solvent 
molecules.   
A detailed analysis of the van der Waals energies for interactions between only the 
sidechain of Arg 452 and the protease revealed significantly higher values for all 
structures compared to the PRWT—p1-p6WT structure (Table IV.2).  However, the overall 
van der waals energies for Arg 452 interactions with the protease were in the same range 
for all structures including the PRWT—p1-p6WT structure (Fig IV.6a-b).   
A significant decrease was observed in the overall van der Waals interactions made by 
30b with the p1-p6 peptide as compared to the PRWT—p1-p6WT structure, which are 
compensated by large increases in interactions of Asp 29b with the the p1-p6 peptide 
(IV.5a-g).  In addition, Ile 47b, Gly 48b and Ile 50b protease residues in all structures 
except PRWT—p1-p6WT structure  made more favorable van der Waals interactions with the 
p1-p6 peptide, further compensating for the loss of interactions. 
In chapter II and other studies (Feher et al., 2002; Maguire et al., 2002), it was 
hypothesized that the L449F mutation would result in increased interactions by this 
residue with the protease due to the larger size of the Phe residue.  This is demonstrated 
by the van der Waals interaction energies listed in Table IV.2 and Fig IV.6c.  A similar 
increase in interactions at Gag 449 is expected in the PRD30N/N88D—p1-p6L449F structure. 
However, a smaller increase in van der Waals interaction energies is observed in the 
PRWT—p1-p6L449F/S451N (Fig IV.6f) structure.  Thus, it appears that a mutation at Gag 449 
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leads to increased interactions at 449 leading to the more efficient processing of the p1-p6 
cleavage site as shown in previous studies (Feher et al., 2002; Maguire et al., 2002). 
Similarly, the larger Asn residue in the peptide with the Gag S451N mutation, causes 
improved van der Waals interactions with the protease as indicated by the lower van der 
Waal interaction energies (Table IV.2).  This increase in interaction energies is mainly 
due to a significant increase in contacts with Arg 8a and, to a lesser extent with Asp 29b 
and 48b, of the protease.  Also, several new hydrogen bonds are observed between Asn 
451 and Arg 8a or water molecules (Fig IV.3d-g).  Together, these changes resulting 
from the S451N mutation are likely to improve p1-p6 recognition by the WT and 
D30N/N88D protease. 
Finally, asparagine 88 to aspartate is a compensatory mutation that commonly occurs 
with the D30N, NFV-resistant protease mutation.  As described in the results, changes in 
the hydrogen bonding network around residue 88 were observed as a result of this 
mutation (Fig IV.4a-g).  Most significantly, in all the WT protease complexes Asn 88 
ND2 forms a hydrogen bond with Thr74 O that is disrupted upon mutation to Asp.  This 
disruption, along with a few other changes in the hydrogen bonding network, serve to 
reorient this residue towards the interior of the molecule.  This change in hydrogen 
bonding was also reported in previously solved structures of the NFV-resistant 
D30N/N88D HIV-1 protease in complex with NFV (PDB 2PYM; (Kozisek et al., 2007). 
This reorientation of Asp 88 and rearrangement of hydrogen bonds were also observed in 
the absence of the D30N mutation (Mahalingam et al., 2001).  Thus, the mechanism by 
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which the N88D mutation improves viral fitness/replicative capacity in the context of the 
D30N mutation is not well undertood.  It is also very likely that this protease mutation 
does not directly play a role in the co-evolution of the p1-p6 cleavage site. 
In summary, the p1-p6 cleavage site co-evolves with the D30N/N88D protease mutations 
as shown in Chapters II and III.  Structural studies described here show that the L449F 
and S451N mutations in the p1-p6 cleavage site significantly increase the overall 
interactions, both by means of hydrogen bonds and van der Waals interactions with the 
protease.  Previous studies have demonstrated that the L449F mutation improves Gag 
processing at this site and it is possible that similar effects on Gag processing maybe also 
be observed with the S451N mutation.  Co-occurance of L449F and S451N within the 
p1-p6 peptide has not been observed previously.  In chapter II, it is hypothesised that van 
der Waals clashes between the two large amino acid residues may prevent this co-
occurance.  However, no such van der Waals clashes were observed in the PRWT-p1-
p6L449F/S451N and the PRD30N/N88D-p1-p6L449F/S451N structures.  Also, the overall van der 
Waals interaction energies did not vary significantly from the structures with single 
mutant peptides.  While it appears that the occurrence of either one of the mutations may 
be sufficient to compensate for the loss of binding efficiency of the WT peptide to the 
mutant protease, whether the compensation is sufficient to prevent co-occurence is not 
clear. 
Interestingly, the differences observed in the interactions between mutant peptide and 
mutant protease were also observed in all the structures WT protease and mutant peptides 
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as well.  Earlier have shown that p1-p6 peptide with the L449F mutation was cleaved 
more efficiently even by the WT protease studies (Feher et al., 2002; Maguire et al., 
2002), suggesting that this mutant peptide is a more efficient substrate than the WT p1-p6 
cleavage site.  This suggests that the co-evolution of this cleavage is not specific for 
particular protease mutations.  This observation is consistent with results from chapter III 
and other studies (Maguire et al., 2002) that this site co-evolves with other primary 
resistance mutations as well.  Earlier kinetic studies and amino acid preference studies 
have suggested that the WT p1-p6 cleavage site may not be the most optimum sequence 
(Feher et al., 2002).  This sub-optimal amino acid sequence results in the later cleavage of 
the p1-p6 site during the processing of Gag.  The coevolution of the p1-p6 site resulting 
in an improved substrate may reestablish the correct order of Gag processing. 
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CHAPTER V 
DISCUSSION
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Despite tremendous advances in scientific research on AIDS and its causative organism, 
HIV, there are still millions of infected people worldwide with no hope for a permanent 
cure nor is there a preventive vaccine that could curb the growing epidemic.  Two 
decades of research have led to the development of several antiviral drugs including 
inhibitors to the viral protease, which have significantly reduced HIV-related morbidity 
and mortality.  The success of these inhibitors is severely compromised due to the 
development of resistance-associated mutations within the protease.  The virus also 
evolves compensatory mutations, not only in the protease but also in the protease 
cleavage sites within Gag, which contribute to increased viral fitness and resistance.  
Drug resistance is a change in molecular recognition where the protease mutates to 
decrease inhibitor binding even as it continues to recognize and cleave its substrates.  A 
better understanding of the underlying mechanisms of drug resistance to protease 
inhibitors (PIs), including substrate co-evolution, will contribute to the design of more 
robust inhibitors that are effective against the drug-resistant protease variants and prevent 
further development of drug resistance.  My dissertation research focused on 
investigating substrate co-evolution and examining the effect this has on viral fitness and 
protease inhibitor susceptibility.  In addition, I performed X-ray crystallographic studies 
to investigate structural changes as a result of this substrate co-evolution. 
In Chapters II and III, I examined viral sequences derived from infected individuals 
treated with protease inhibitors, for mutations in the cleavage sites that correlated with 
primary drug resistance mutations.  I investigated the effect of these correlated mutations 
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on viral fitness and phenotypic susceptibilities to various PIs.  Finally, I studied protease-
p1-p6 complexes, in Chapter II and IV, to probe the underlying structural changes 
occurring as a result of this co-evolution. 
Co-evolution of HIV-1 Protease and the Viral Substrates 
Associations between specific mutations in the protease and its cleavage sites have been 
reported previously, and were demonstrated to act as compensatory mutations (Bally et 
al., 2000; Doyon et al., 1998; Maguire et al., 2002; Mammano, Petit, and Clavel, 1998; 
Zhang et al., 1997).  These associated mutations are likely to become more common as 
the number of infected individuals receiving protease inhibitor therapy increases. 
Therefore I performed statistical analyses to investigate co-evolution of substrate 
cleavage site and protease mutations that are the primary cause of PI resistance (Chapters 
II and III).  My initial study involving a small set of viral sequences from infected 
individuals that are resistant to protease inhibitor therapy (Chapter II) revealed that the 
p1-p6 cleavage site mutations correlate with the NFV-resistant D30N/N88D protease 
mutations.  In addition to this, I identified several other correlations between cleavage 
site mutations and primary drug resistant mutations in Chapter III.  Of the four cleavage 
sites analyzed, mutations are most frequent in the NC-p1 and p1-p6 cleavage sites and 
correlate with PI resistance protease mutations, in different combinations.   
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Effect of Substrate Co-evolution on Viral Fitness and PI Susceptibility 
Primary PI resistance mutations, especially in the active site, reduce both protease 
catalytic efficiency and viral replicative capacity (RC) (Bleiber et al., 2001; Croteau et 
al., 1997; Martinez-Picado et al., 2000; Martinez-Picado et al., 1999).  Several studies 
have demonstrated that the evolution of compensatory mutations within cleavage sites 
leads to improved viral fitness compensating for the loss in fitness resulting from the 
protease resistance mutations (Doyon et al., 1996; Mammano, Petit, and Clavel, 1998; 
Robinson et al., 2000; Zhang et al., 1997).  However, in my studies, no significant 
differences in viral fitness were observed in viruses with protease resistance mutations in 
the presence and absence of mutations within the Gag cleavage sites (Chapter III).  This 
reflects studies by Dam et al. (Dam et al., 2009), where, although RC was fully restored 
by cleavage site mutations in the context of WT pNL43 Gag-patient derived protease-RT, 
the reversion of the same cleavage site mutations to WT in the context of patient derived 
Gag had little impact on RC.  Likely there are fitness determinants in the down-stream 
region of Gag, especially the p1-p6/p6* region, although mechanism for this is poorly 
understood (Myint et al., 2004; Whitehurst et al., 2003).   
Additionally, in Chapter III, I statistically analyzed the effect of the observed correlations 
on phenotypic susceptibilities to various PIs, and these correlations were observed to 
significantly affect PI susceptibilities.  In most instances, a significant decrease in 
phenotypic susceptibility to particular protease inhibitors was observed.  Although 
mutations at either Gag 431 or Gag 437 were not associated with D30N/N88D protease 
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mutations, significantly lower PI susceptibilities were observed.  A similar trend was also 
observed with Gag A431V and the L90M protease mutation.  Mutations at either of these 
residues within the NC-p1 cleavage site likely directly enhance resistance to PIs as was 
observed and demonstrated previously (Dam et al., 2009; Parkin, 2005).  At least in the 
case of the Gag A431V mutation this is likely due to enhanced Gag processing at this site 
as demonstrated by Nijhuis et al., (Nijhuis et al., 2007).  Thus, I observed that Gag 
cleavage site mutations enhance resistance to PIs in combination with primary drug 
resistance mutations in the protease. 
Structural Insights into Substrate Co-evolution 
As observed in Chapter III, the NC-p1 and p1-p6 cleavage sites mutated very frequently 
and were associated with primary drug resistance mutations in the protease.  Although 
several studies demonstrated the effect of both the Gag A431V and Gag L449F mutations 
on Gag processing (Feher et al., 2002; Maguire et al., 2002), only a few studies examined 
the structural changes resulting from substrate co-evolution (Prabu-Jeyabalan et al., 
2004).  To this end, I performed structural studies using the co-evolution of the p1-p6 
cleavage site with the D30N/N88D protease mutation as an example.  Within the p1-p6 
cleavage site, mutations occur specifically at Gag 449, Gag 451 or Gag 453 (Chapters II 
and III). Leu 449 mutated frequently to a Phe whereas Ser 451 mutated to an Asn.  
However, the simultaneous occurrence of these two mutations was infrequent and I 
hypothesized to be due to unfavorable van der Waals contacts (Chapter II).  Since Pro 
453 is located outside the substrate-binding pocket and is frequently disordered in crystal 
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structures of protease-p1-p6 complexes no meaningful structural conclusions can be 
made.  Therefore this mutation was not included in this structural analysis.  Thus, WT 
and D30N/N88D protease variants in complex with p1-p6 variants including either 
L449F or S451N or both mutations, were analyzed for structural changes resulting from 
this co-evolution. 
Structural studies in Chapter IV show that both L449F and S451N mutations in the p1-p6 
cleavage site significantly increase the overall interactions with the protease active site, 
both by means of hydrogen bonds and van der Waals interactions, and is in agreement 
with previous studies in the case of the L449F mutation (Feher et al., 2002).  The L449F 
mutation has been demonstrated to improve Gag processing at this site (Maguire et al., 
2002).  Further studies are warranted to investigate if similar effects on Gag processing 
are observed with the S451N mutation.  The two larger residues at Gag 449 and 451, Phe 
and Asn, respectively are able to pack well in both PRWT-p1-p6L449F/S451N and the 
PRD30N/N88D-p1-p6L449F/S451N structures.  The occurrence of either one of the mutations 
may be sufficient to compensate for the loss of binding efficiency of the WT peptide to 
the mutant protease, but there is no obvious selective advantage for having both changes 
simultaneously. 
The overall structures of the complexes are very similar to each other and the PRWT—p1-
p6WT structure though significant differences are observed within the p1-p6 peptide, 
which affect the interactions with protease 30b.  Modeling studies in Chapter II suggest 
that the D30N mutation likely affects p1-p6 recognition as a result of disruption of strong 
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hydrogen bond interactions between 30b and Arg 452 of the p1-p6 peptide.  This was 
confirmed in the crystal structures of D30N/N88D protease complexes but unexpectedly 
also the WT protease complexes with variants of p1-p6  (Chapter III).  The disruption of 
the interaction between 30 and 452 is due to a large conformational change involving 
both the backbone and side chain of R452.  This conformational change cannot be 
attributed to differences in crystal packing or buffer conditions as there are no crystal 
contacts or symmetry related contacts in that region, nor are there any consistent 
differences in buffer conditions.  Rather, the rearrangements of the packing of the 
substrate either due to changes of the protease or the substrate result in a suboptimal 
packing and thus change in orientation of R452.  
Contrary to the predictions made in Chapter II, my structural analyses reveal that the 
differences observed in the interactions between mutant protease and mutant peptide 
compared to WT protease with WT p1-p6 peptide were also observed in structures of WT 
protease and mutant peptides.  Earlier studies demonstrating efficient cleavage of the 
L449F p1-p6 peptide even by the WT protease studies (Feher et al., 2002; Maguire et al., 
2002), show that this mutant peptide is a more efficient substrate than the WT p1-p6 
cleavage site.  This, and my results from Chapter III suggest that the co-evolution of the 
p1-p6 cleavage may not be specific for particular protease mutations, however may play a 
role in modulating Gag processing.  
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Future Directions 
Structural Changes due to Substrate Co-evolution  
I’ve shown, in Chapter III, that different cleavage sites mutate depending on the mutation 
at residue 50.  NC-p1 mutations correlate with the I50L protease mutation whereas with 
I50V, we observe correlated mutations within the p1-p6 cleavage site.  Structural studies 
of wild-type and mutant NC-p1 and p1-p6 in complex with I50L and I50V proteases 
respectively, will give information regarding structural changes as a result of the 
correlated mutations.  Additionally, these studies will give insights into this differential 
pattern of co-evolution of NC-p1 and p1-p6 substrates with the I50L and I50V protease 
mutations respectively.  Similar studies can be performed with other observed co-
evolving pairs of mutations. 
Effect of Substrate Co-evolution on Gag Processing  
The WT p1-p6 cleavage site, like the NC-p1 cleavage site, may not be the most optimum 
sequence (Feher et al., 2002) and this sub-optimal amino acid sequence likely influences 
the sequential processing of Gag.  Both A431V and L449F mutations within NC-p1 and 
p1-p6 cleavage sites, respectively, alter Gag processing by the wild-type protease.  
Previous studies have shown that both Gag A431V and Gag L449F mutations enhance 
Gag processing and influence viral fitness (Feher et al., 2002; Maguire et al., 2002; 
Maguire et al., 2001; Myint et al., 2004).  The enhanced processing of Gag A431V is 
likely the result of additional contacts with the protease (Prabu-Jeyabalan et al., 2004).  
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Peptides corresponding to the p1-p6 cleavage site with the L449F mutation have 
previously been shown to be a better substrate for the protease (Feher et al., 2002).  In 
addition, this mutation has been shown to enhance Gag processing (Maguire et al., 2002). 
Thus, to study the effect of mutations in the protease and/or the co-evolving cleavage 
sites, one can measure the relative cleavage rates at different sites during Gag processing 
by the protease as shown by Pettit et al (Pettit et al., 2002).  The relative rates of cleavage 
of wild-type and mutant Gag, containing the p1-p6 mutations, by the D30N/N88D 
protease could be assayed and compared with processing by the wild-type protease.  
Similar studies should be performed with the I50L and I50V proteases to determine the 
effect of NC-p1 and p1-p6 co-evolution on Gag processing.  I predict that the above 
mentioned protease mutations will likely affect Gag processing, either by slowing down 
the relative rates or by changing the order of cleavage between the cleavage sites.  If the 
order of cleavage is altered, possibly the co-evolved substrate sites may restore the 
correct order of Gag processing.  Thus these experiments to study processing of full 
length Gag variants by WT and mutant proteases will give insights into how co-evolving 
mutations influence Gag processing, and in turn influence viral fitness and/or resistance 
to various inhibitors. 
Influence of Gag Non-Cleavage Site Mutations on Resistance 
The p1-p6Gag-p6pol regions of Gag/Gag-Pol is one of the least understood regions of the 
viral genome.  The p6Gag is known to facilitate viral budding (Gottlinger et al., 1991; 
Huang et al., 1995; Yu et al., 1995), Pol and Env packaging (Ott et al., 1999; Yu et al., 
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1998), and has also been implicated in controlling particle size (Garnier et al., 1999; 
Garnier et al., 1998), and p6Pol acts as a regulator of protease activation (Chatterjee et al., 
2005; Chiu et al., 2006; Dautin, Karimova, and Ladant, 2003; Louis et al., 1998; Partin et 
al., 1991).  The p6Gag protein has a highly-conserved N-terminal P(T/S)AP motif which 
mediates binding to the cellular protein Tsg101 (Demirov, Orenstein, and Freed, 2002; 
Garrus et al., 2001; Martin-Serrano, Zang, and Bieniasz, 2001; Pornillos et al., 2002; 
VerPlank et al., 2001).  There have been several reports that suggest that changes in this 
region of Gag, including duplications and/or insertions, in viruses from patients 
undergoing anti-retroviral therapy lead to increased infectivity and increased resistance to 
RT and protease inhibitors (Doyon et al., 1998; Gallego et al., 2002).  In Chapter III I 
showed that mutations within the PTAP region were more frequent in combination with 
protease resistance mutations than in the absence.  These mutations/ duplications/ 
insertions may improve viral fitness and/or enhanced resistance to protease inhibitors, 
either in the presence or absence of protease resistance mutations.  A statistical analysis 
can be performed to look for association between these changes in p6Gag and replicative 
capacity and resistance to protease inhibitors.  One can also investigate the association of 
changes in the p6Gag region with protease resistance mutations.  In depth viral studies 
incorporating these changes within the p6Gag could give insights into the various 
mechanisms leading to alterations in viral fitness and resistance.  
More recently, Parry et al., have demonstrated that mutations in the matrix and partial 
capsid in the N-terminal regions of Gag fully restore RC to WT levels and thus play a key 
role in fitness (Parry et al., 2009).  More specifically, their studies have narrowed down 
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the mutations to the following: R76K, Y79F, S81A and a double insertion Q116TQ.  In 
addition to improving fitness, these mutations significantly enhanced resistance to PIs 
even in the absence of PI resistance mutations in the protease (Parry et al., 2009).  
Although this study was based on a single clinical isolate, other mutations in the N-
terminal region of Gag outside of the cleavage sites may influence viral fitness and/or 
protease inhibitor resistance.  The Monogram Biosciences database could be examined 
and statistical analyses performed to investigate resistance mutations in the protease and 
their associations with mutations in the N-terminal region of Gag.  Biochemical and viral 
studies can be performed to investigate the effect of these mutations on Gag processing, 
viral fitness and resistance to protease inhibitors.  Additionally, modeling studies and/or 
structural studies could provide insights into how mutations in these distant regions of 
Gag are likely to influence viral fitness and resistance to protease inhibitors.  These 
studies will also increase our understanding of the structure of Gag and tertiary 
interactions between the protease and Gag. 
Implications for Diagnosis and Treatment and Drug Design Strategies 
Structural and biochemical insights into mechanisms by which substrate co-evolution 
alters viral fitness and resistance will enhance our understanding of substrate recognition 
and cleavage as well as the development of resistance.  The detailed structural analyses of 
various protease-substrate complexes, including those I described in Chapter III, in 
combination with our knowledge of interactions between mutant protease variants and 
existing protease inhibitors will significantly contribute to design of better protease 
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inhibitors.  Structural studies of the co-evolving mutations within protease and the NC-p1 
and p1-p6 cleavage sites could lead to the calculation of a new substrate envelope, as has 
been done previously with wild type protease-substrate complexes.  New inhibitors may 
be designed to fit within the new substrate envelope such that they are functional not only 
against mutant protease variants and but will also leave no room for co-evolution. 
Resistance testing strategies involve phenotypic drug susceptibility assays that measure 
level of resistance to various protease and RT inhibitors.  In addition, replicative capacity 
assays are also performed to measure infectivity of the virus, which reflects the overall 
viral fitness.  Currently, these are single-cycle replicon assays that include the PR and RT 
regions amplified from patient plasma samples.  However, my research in Chapter III 
showed that mutations within the NC-p1 and p1-p6 cleavage sites enhanced resistance to 
protease inhibitors, in combination with protease resistance mutations.  Additionally, 
several other studies also demonstrated that mutations within the NC-p1 cleavage site 
enhanced resistance even in the absence of resistance mutations within the protease.  
Thus, these studies suggest that mutations within Gag must also be considered when 
assessing resistance to various protease inhibitors. 
Summary 
Drug resistance is a change in molecular recognition where, balance is maintained 
between loss of inhibitor binding even as substrate recognition is maintained.  When this 
balance is disturbed, the substrates are likely to evolve so as to maintain viral fitness even 
as they contribute to drug resistance.  My research showed that the NC-p1 and p1-p6 
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cleavage sites co-evolve even as the protease continues to accumulate primary resistance-
associated mutations within the active site.  Though NC-p1 and p1-p6 co-evolution are 
observed not to contribute significantly to viral fitness, there were extensive effects on 
phenotypic susceptibilities to various protease inhibitors.  In most instances I observed a 
significant decrease in susceptibility to various protease inhibitors, whereas there were 
cases where the co-evolution actually increased susceptibility to particular inhibitors.  My 
structural studies of the p1-p6 co-evolution with the D30N/N88D protease showed that 
loss of p1-p6-protease interactions as a result of the D30N mutation is likely to be 
compensated by improved van der Waals contacts as a result of correlated mutations in 
the p1-p6 cleavage site, in a manner similar to the A431V–V82A co-evolution.  These 
findings only just begin to describe the interplay between protease and substrate co-
evolution, details of which will be elucidated as more extensive viral sequencing is 
routinely performed on patient isolates.  Thus, my research furthers our understanding of 
the evolution of resistance to protease inhibitors and also provides insights into the 
biology of HIV-1.  Additionally, the results presented in my thesis dissertation, and by 
extension to other regions of Gag, could also be used in future strategies to design more 
potent protease inhibitors. 
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APPENDIX I 
VIRAL ASSAYS – MEASUREMENTS OF PHENOTYPIC 
SUSCEPTIBILITIES AND REPLICATIVE CAPACITIES
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The PhenoSense Assay™  
The PhenoSense Assay™ is used by Monogram Biosciences for rapid and accurate 
measurement of susceptibility of clinical isolates to most currently available anti-
retroviral drugs.  In Chapter III, I used both sequence and drug susceptibility data 
generated to perform statistical analyses to examine the effect of substrate co-evolution 
on resistance to various protease inhibitors.  The assay, adapted from Petropoulos et 
al.,(Petropoulos et al., 2000)  is described below in detail. 
Antiviral Drugs.  The following protease inhibitors are used to determine the phenotypic 
susceptibility profile of the patients’ HIV-1 isolates: amprenavir (APV), atazanavir 
(ATV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), saquinavir 
(SQV), and tipranavir (TPV). 
Preparation of sample and amplification.  The patient viral particles are pelleted by 
centrifugation at 20,400 x g for 60 min for 1ml of plasma.  The viral particles are 
disrupted and part of the viral genome is amplified with a forward primer containing the 
ApaI site and a reverse primer containing the PinAI site.  The 1.5kb amplification product 
includes the NC-p1-p6 cleavage sites in gag and the PR and RT coding regions within 
pol.   
Resistance test vectors (RTV).  The retroviral vector used to measure drug 
susceptibilities is constructed using a modified infectious vector derived from the NL4-3 
HIV-1 clone.  The vector, referred to as an indicator gene viral vector (IGVV), is 
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replication defective and lack the PR and RT genes.  A region of the envelope (env) gene 
is deleted and in its place is a luciferase expression cassette.  The amplified patient-
derived viral PR and RT regions were digested using the ApaI and PinAI restriction sites, 
purified by agarose gel electrophoresis and then ligated to the IGVV DNA that was 
digested using the same restriction enzymes, thus forming the RTVs.  Libraries of the 
RTVs are prepared in order to capture and preserve the heterogeneity of the patient viral 
populations.  Ligation reactions are used to transform competent E Coli and plated onto 
agar.  The number of colonies are used as an estimate of the number of viral segments in 
each RTV library.  Libraries less than 100 clones are not considered representative of the 
patient virus.   
Protease Inhibitor Susceptibility Assay (Fig A I.1).  Viral stocks for the assay are 
prepared by co-transfection of human embryonic kidney 293 cells (HEK 293, host cells) 
with RTV plasmid DNA and an expression vector encoding the ENV proteins of 
amphotrophic murine leukemia virus.  Host cells are trypsinized 16 hours after 
transfection and distributed into 96 well plates containing serial dilutions of protease 
inhibitors.  This was done for each of the protease inhibitors tested.  Viral particles 
generated in the presence of the protease inhibitors are harvested 48 hours after 
transfection and used to infect fresh 293 cultures in 96 well plates in the absence of 
drugs.  Measurement of luciferase activity 48 hours after infection indicates the amount 
of replication.  The protease inhibitors affect luciferase activity in a dose-dependent 
manner, thus allowing for a quantitative measure of drug susceptibility.  Low levels of  
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Figure A I.1 
 
  B 
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Figure A I.1:  Structure of the resistance test vector (RTV) and overview of the 
assay.  (A) PR and RT sequences from patient-derived viral samples are inserted into a 
luciferase containing viral vector using the ApaI and PinAI restriction sites. (B) RTV 
DNA and Amphotropic MLV DNA are transfected into cells and viral particles 
harvested.  After harvesting, the viral particles are used to infect fresh target cells.  
Measurement of luciferase activity in the target cells quantitates the ability of the virus to 
complete one round of replication.  When measuring replicative capacity, this assay is 
performed in the absence of any anti-retroviral drugs.  Susceptibility to either protease 
inhibitors or RT inhibitors is measured by adding protease inhibitors to transfected cells 
and RT inhibitors to infected cells.
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luciferase activity is indicative of a susceptible virus whereas high levels of luciferase 
activity indicate a resistant virus. 
The percent inhibition is calculated as follows: [1 – (luciferase activity in the presence of 
drug/luciferase activity in the absence of drug)] X 100.  For each drug concentration this 
is repeated several times and the mean percent inhibition determined by a bootstrapping 
procedure.  This data is displayed by plotting the percent inhibition of luciferase activity 
versus log10 drug concentration.  Inhibition curves defined by the four-parametric 
sigmoidal function f(x) = a – [b/(1+(x/c)d)] are fit to the data and used to calculate drug 
concentrations required to inhibit viral replication by 50% (IC50).  This calculated IC50 
from the sample virus is then compared with the IC50 for a drug-sensitive reference NL4-
3 strain of HIV-1, to calculate and determine the fold change in drug susceptibility.  
Replicative Capacity™  
Replicative Capacity™ of HIV measured by Monogram Biosciences gives a direct 
measure of infectivity i.e., the ability of the virus to infect target cells (PR activity) and to 
complete the reverse transcription and integrase steps of the life cycle (RT and Int 
activity).  As described in Chapter III, I used both sequence and replicative capacity to 
examine the effect of substrate co-evolution on viral fitness.  The replicative capacity of 
clinical isolates was measured as described in Deeks et al., (Deeks et al., 2001) using a 
modified version of the PhenoSense Assay™described in the previous section. 
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Assay description (Fig A I.1).  Patient-derived viral PR and RT are prepared and 
amplified and resistance test vectors (RTV) are constructed as described in the previous 
section for the PhenoSense Assay™.   The viruses are harvested 48 hours after 
transfection.  The amount of virus produced is evaluated and then inoculated into fresh 
cell cultures and incubated for 48 hours. Luciferase activity in infected cells is 
determined after normalizing for the amount if input virus.  This luciferase activity gives 
a measure of the ability of the virus to replicate in the absence of anti-retroviral drugs. 
The relative RC of the patient-derived virus is calculated as a ratio of the luciferase 
activity from patient-derived viruses to luciferase activity from reference virus (wild-
type) derived from a molecular clone of HIV-1 (NL4-3).  RC measurements are then 
expressed as a percent of the wild-type reference virus.  Measurements less than 100 % 
indicate reduced replicative capacity of the virus when compared to that of the reference 
wild-type virus. 
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Investigate co-evolution of Gag cleavage sites and primary PI resistance-associated 
mutations in the protease 
1. Co-evolution of Gag cleavage sites with D30N/N88D protease mutations 
I investigated the association of Gag cleavage site mutations with the D30N/N88D 
protease mutations.  The analysis focused on qualitative changes in cleavage-site 
sequences, as compared to the HXB2 sequence, that covary with the D30N/N88D drug-
resistant substitutions in the protease.  For each protease sequence with the D30N/N88D 
mutations, the corresponding substrate cleavage sites were scored for the presence or 
absence of mutations.  The simultaneous occurrence of cleavage-site mutations and the 
D30N/N88D protease mutations were compared for each of the seven substrates studied.   
Method.  In order to examine association between mutations in the Gag cleavage sites 
and the D30N/N88D protease mutations, I used the Chi-square test of independence. The 
null and alternate hypotheses tested are:  
 
H0 : Association of mutations in the cleavage sites and the D30N/N88D protease 
mutations are independent. 
 
HA : Mutations in the cleavage sites and the D30N/N88D protease mutations are not 
independent. 
The Chi-square test of independence is used to compare two nominal variables, each with 
two or more variables and tests the null hypothesis that the two variables are independent 
and is calculated as follows: 
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X2 = 
 
(Oi − Ei)2
Ei
 
 
 
 
 
 
i=1
k
∑          (1) 
In this case there are two nominal variables: the presence and absence of particular 
cleavage site mutations each with two variables, the presence or absence of D30N/N88D.  
A data set like this is called a 2 X 2 contingency table and the Chi square statistic, X2, 
was calculated by the following shortcut formula: 
X2 = 
 
n(ad − bc)2
(a + c)(b + d)(a + b)(c + d)        (2) 
where a , b, c, and d are the observed cell frequencies.  The degrees of freedom for a 2 X 
2 table is calculated to be 1 using the rule 
 
(r −1)(c −1) , where r is the number of rows and 
c, the number of columns.  I also used the Yates correction for continuity when the total 
number of samples, N, is less than 20 or when the expected cell frequency was smaller 
than 5.  The corrected Chi-square is then calculated as follows: 
X2corrected = 
 
n((ad − bc) − 0.5n)2
(a + c)(b + d)(a + b)(c + d)       (3) 
I used an interactive web-based Pearson’s Chi-square calculator to calculate the Chi-
square statistic based on which the null hypothesis (
 
H0 ) is accepted or rejected.  
Associations where the p values are < 0.05 are considered significant. 
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In addition, I calculated the phi correlation coefficient to determine positive or negative 
correlations. The phi coefficient of correlation is used to measure the strength of 
association between two variables.  This method is used when the two variables being 
studied are binary variables i.e. yes or no variables coded by 1 or 0 respectively.  For this 
kind of binary data, this is modified and expressed in terms of p(for 1) and q(for 0) as 
rφ(or simply φ) =        (4) 
  
The phi coefficient of correlation is also related to the X2 in the following manner: 
φ = 
 
X 2
N           (5) 
I used the above equation to calculate the phi coefficient of correlation in this study. The 
phi coefficients vary from -1 (perfect negative correlation) to +1 (perfect positive 
correlation) through 0 (no correlation). 
2. Co-evolution of Gag cleavage sites with primary PI resistance protease 
mutations 
I wanted to further investigate substrate co-evolution and so extended this study, beyond 
the NFV-resistant mutations, to other primary drug resistance mutations.  Anti-HIV drugs 
have become increasingly accessible (in the US at least) and resistance testing has 
become more common.  As a result, we had access to a larger database of sequences. 
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This analysis also focused on qualitative changes in the NC-p1, p1-p6, autoproteolysis 
and the Pr-RT cleavage-site sequences, as compared to the HXB2 sequence, that covary 
with several primary resistance mutations within the protease.  The following protease 
mutations, singly or in combination, were analyzed in this study: D30N, I50V/L, V82A, 
I84V, N88D and L90M. 
Method. As in the previous analysis, we chose to use the Chi-square test of 
independence, as described in the previous section, to test for the association of cleavage 
site and protease mutations.  Since this database consisted of more than 39,000 
sequences, scripts were used to extract sets of data and the Chi-square test was computed 
using the software R (R function chisq.test).  Since the same dataset was used to test for 
cleavage site mutations with several protease mutations, adjustments were made for 
multiple testing using the Bonferroni correction.  Thus, if there are n number of 
hypotheses being tested on a single set of data, then the significance level is 1/n times 
significance level if only one hypothesis is being tested. In other words, the p-values are 
multiplied by n  and the corrected p-values < 0.05 indicate statistical significance.  The 
Yates correction was not needed for this set of sequences as the dataset was very large. 
Results and Discussion.  The Pearson Chi-square is the simplest and one of the most 
commonly used tests for significance of association between two categorical variables.  
Covariation between cleavage site mutations and resistance mutations in the protease 
were observed in both studies.  In the first study, I observed that D30N/N88D and p1-p6 
substrate site mutations were significantly correlated and the phi values indicate a 
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positive correlation. Mutations at NC-p1 also covaried with the D30N/N88D mutations in 
the protease.  However, in contrast with the p1-p6 site, I observed that mutations within 
the NC-p1 cleavage site were negatively correlated to the protease D30N/N88D 
mutations indicated by a negative phi value.  
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Investigate the effect of substrate co-evolution on viral fitness and phenotypic 
susceptibilities to various protease inhibitors. 
In order to study the effect of substrate co-evolution on viral fitness and drug resistance, 
Replication CapacityTM(RC) and phenotypic susceptibilities for viruses including the 
protease mutations of interest with and without Gag cleavage site mutations were 
extracted and analyzed.  RC was determined and expressed as a percentage relative to 
that of a reference virus, NL4-3 (Deeks et al., 2001). Phenotypic susceptibilities are 
expressed as fold change (FC) in IC50 of the patient virus relative to that of the drug-
sensitive reference, NL4-3.  
Method. We used the Mann-Whitney test in order to examine if substrate co-evolution 
had an effect on PI susceptibility and RCs. The Mann-Whitney test can be used if 
following assumptions of the are met, as in this study: 1) the two samples being tested are 
independently and randomly drawn, 2) the variables are ordinal and continuous and 3) the 
difference in populations, if any, is with respect to their medians.  
This test assesses whether a difference exists between the two samples of observation. 
The null hypothesis here is that the two samples are drawn from a single population and 
therefore, their probability distributions are equal.  In this case, the null and alternate 
hypotheses tested are: 
 
H0 : 
 
MX = MY   
 
HA : 
 
MX ≠ MY  
where MX is the median of RCs of a set of viruses with mutations in both the particular 
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cleavage site and protease and MY is the median of a set of viruses with particular 
mutations in the protease alone in the absence of cleavage site mutations.  This is a two-
tailed test. The level of significance α = 0.05.  The expectation is that mutations in the 
cleavage site would affect RC or PI susceptibility when present in combination with 
primary resistance-associated protease mutations.  
In order the compute the test statistic the two samples are combined and ranked in 
ascending order.  If two or more observations are tied, their rank is equal to the mean of 
the rank positions for which they are tied.  The test statistic, U, is calculated as follows: 
 
U = S − n(n +1)2  
where n is the number of sample X observations (sequences with both the particular 
cleavage site mutation and protease mutation being analyzed) and S is the sum of ranks of 
sample X.  If the computed values of U is either less than 
 
ωα / 2  or greater than 
 
ω1−(α / 2) 
then the null hypothesis is rejected, where 
 
ωα / 2  is the critical value of U (for a two-sided test as in this case), n is number of samples 
of X and m, number of samples of Y.  However, if either n or m is greater than 20, then 
we calculate a new statistic z, as follows: 
 
z = U −mn /2
mn(n + m +1) /12  
and compare it with critical values of the standard normal distribution to either reject or 
accept the null hypothesis.  
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The R software environment, version 2.4.1 (http://www.r-project.org) was used to 
perform the Mann-Whitney test to calculate the test statistic, as well as the p-values (R 
function “Wilcoxon.test”). Adjustments were made for multiple testing using the 
Bonferroni method.  The corrected p-values < 0.05 were taken to be statistically 
significant. 
Results and Discussion.  In majority of cases, substrate co-evolution had no significant 
effect on replicative capacity.  In contrast, in most instances where substrate co-evolution 
is seen, there was significant decrease in susceptibility to one or more protease inhibitors. 
The Mann-Whitney test is used in same situations as the student’s t-test.  We chose the 
Mann-Whitney test for the following reasons: 1) Mann-Whitney is usually used when the 
data is ordinal, as in this case, 2) Mann-Whitney is much more robust as compared the t-
test as it is less likely to give falsely significant results as a result of one or two outliers, 
3) the t-test is always used when populations are normally distributed, whereas for 
distributions that are not normal and/or very large sample sizes, as in this case, the Mann-
Whitney test is much more efficient, and 4) Mann-Whitney test can be used even if the 
shapes of distribution of the two samples are different whereas in the case of the t-test, 
the distributions are required to be the same. Though the Mann-Whitey test is commonly 
used to test for differences in medians, this is not strictly true and can also be used to test 
for differences in means of a population. The two-sample test, as used here, may be 
thought of as testing the null hypothesis that the probability of an observation from one 
population exceeding an observation from the second population is 0.5.  Thus, the Mann-
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Whitney test was used to test the difference in means in the case of RCs whereas in the 
case of phenotypic susceptibilities, it was used to test difference in median fold change in 
IC50. Though a formal test for determining the distribution was not performed, the 
Mann-Whitney test was used here, as it is the best-known non-parametric tests for 
significance. 
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Investigate whether there were significant differences in the average number of 
secondary protease mutations in viruses with or without particular Gag mutations  
In order to rule out the possible effect of additional protease mutations we examined if 
there were differences in the average number of secondary mutations in viruses with 
particular protease mutations in the presence and absence of Gag mutations. 
Method.  The student’s t-test was used to evaluate the difference in the average number 
of secondary protease mutations in viruses with and without particular Gag mutations.  
The student’s t-test maybe used if the following assumptions are met, as in this study: 1) 
the two sample populations are normally distributed and, 2) the variances are equal and 
3) data used should be sampled independently from the two populations being compared. 
The t-test assesses whether a difference exists between the means of the two samples. 
The null hypothesis here is that the means of the two populations are equal.  In this case, 
the null and alternate hypotheses tested are: 
 
H0 : 
 
mx = my   
 
HA : 
 
mx ≠ my  
where mX is the average number of secondary mutations in a set of viruses with mutations 
in both the particular cleavage site and protease and mY is the average number of 
secondary mutations in a set of viruses with particular mutations in the protease alone in 
the absence of cleavage site mutations.  This is a two-tailed test. The level of significance 
α = 0.05.  We are testing to see if the mean number of secondary mutations is different 
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between the two populations which could somehow affect the median drug 
susceptibilities of these two populations to various protease inhibitors. 
In order to examine if the means of the two populations are equal the following 
calculations are performed:  
 
t = X1 − X2
SX1X 2 ⋅
1
n1
+
1
n2
 where 
 
 
SX1X 2 =
(n1 −1)SX12 + (n2 −1)SX 22
n1 + n2 − 2
 
 
SX1X 2 is an estimate of the common standard deviation of the two samples, where n is the 
number of samples, 1= group one and 2 = group 2.  n –1 is the number of degrees of 
freedom for either group and n1+ n2 – 2 is the total number of degrees of freedom and is 
used in significance testing.  Using the above equations we can compute the 95% 
confidence interval for the difference in population mean.  If the interval includes zero, 
then we can conclude that the population means may be equal. Additionally, the test 
statistic can be used to calculate the p-value.  p-values < 0.05 are considered significant. 
The R software environment, version 2.4.1 (http://www.r-project.org) was used to 
perform the t-test test to calculate the test statistic, as well as the p-values (R function 
“t.test”). Adjustments were made for multiple testing using the Bonferroni method.  The 
corrected p-values < 0.05 were taken to be statistically significant. 
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In a similar manner, we also used the t-test to investigate the effect of Gag cleavage site 
mutations on protease inhibitor susceptibility, in the absence of resistance mutations in 
the protease.  Sequences with and without Gag mutations in the absence of protease 
mutations were extracted from the database.  The difference in mean FC in IC50s to 
various protease inhibitors was evaluated using the t-test as described in the preceding 
section.   
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